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STRUCTURAL BASIS FOR REGULATED INHIBITION AND SUBSTRATE 
SELECTION IN YEAST GLYCOGEN SYNTHASE 
 
Glycogen synthase (GS) is the rate limiting enzyme in the synthesis of 
glycogen. Eukaryotic GS catalyzes the transfer of glucose from UDP-glucose to 
the non-reducing ends of glycogen and its activity is negatively regulated by 
phosphorylation and allosterically activated by glucose-6-phosphate (G6P). A 
highly conserved cluster of six arginine residues on the C-terminal domain 
controls the responses toward these opposing signals. Previous studies had 
shown that tetrameric enzyme exists in three conformational states which are 
linked to specific structural changes in the regulatory helices that carry the cluster 
of arginines.  These helices are found opposite and anti-parallel to one another at 
one of the subunit interfaces. The binding of G6P beneath the regulatory helices 
induces large scale conformational changes which open up the catalytic cleft for 
better substrate access. We solved the crystal structure of the enzyme in its 
inhibited state and found that the tetrameric and regulatory interfaces are more 
compacted compared to other states. The structural consequence of the tighter 
interfaces within the inhibited state of the tetramer is to lower the ability of 
glycogen chains to access to the catalytic cleft. Based on these observations, we 
developed a novel regulatory feature in yeast GS by substituting two of its 
conserved arginine residues on the regulatory helix with cysteines that permits its  
vii 
activity to be controlled by reversible oxidation/reduction of the cysteine residues 
which mimics the effects of reversible phosphorylation. In addition to defining the 
structural changes that give rise to the inhibited states, we also used X-ray 
crystallography to define the mechanism by which the enzyme discriminates 
between different UDP-sugar donors to be used as substrates in the catalytic 
mechanism of yeast GS. We found that only donor substrates can adopt the 
catalytically favorable bent conformation for donor transfer to a growing glycogen 
chain. 
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INTRODUCTION 
1. Glycogen 
 In nature, glucose polymerization is a universally adapted mechanism to 
store glucose as a metabolic reserve during times of nutritional sufficiency, which 
can be rapidly mobilized when demand exceeds available resources (1). In 
plants, glucose is stored in the form of starch, which is composed of amylopectin 
(Figure 1B), a branched semi-crystalline polysaccharide, and amylose (Figure 
1A), an unbranched polymer of glucose (2) (3). In bacteria, archaea and animals, 
glucose gets stored in the form of glycogen (Figure 1C), a highly branched 
osmotically inert polymer of glucose (1).  
 
Figure 1. Polymerization of glucose residues.   
 
In humans, the major sites of glycogen storage are skeletal muscle and 
liver, but several other tissue types like heart, brain and adipose are also capable 
of synthesizing the polysaccharide (1). Glycogen is an important energy source 
during times of nutritional depletion. In particular, liver glycogen is responsible for 
Glycogen 
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maintaining blood glucose levels for tissues such as the brain, which depends 
mostly on glucose as an energy source. In contrast, skeletal muscle glycogen is 
limited to acting as an internal cellular energy reserve because muscle lacks the 
ability to export glucose derived from glycogen. Glycogen metabolism in the liver 
and skeletal muscle is highly regulated. Enzymatic defects in the processing of 
glycogen synthesis and breakdown result in a class of diseases called Glycogen 
Storage Disease (GSD) (1, 4). There are currently eleven known diseases 
(Table1) that fall under the GSD category affecting at least 1 in every 40,000 live 
births, worldwide (5-7). 
 
GSD 
Enzyme 
deficiency 
Eponym Development and prognosis 
Type 0 Glycogen synthase  Occasional muscle cramping 
Type I 
Glucose-6-
phosphatase 
Von Gierke’s 
disease 
Growth failure 
Type II Acid α-glucosidase Pompe’s disease 
Muscle weakness and death by 
age ~2 
Type III 
Glycogen 
debranching  
enzyme 
Cori’s disease Myopathy 
Type IV 
Glycogen branching  
enzyme 
Andersen disease Failure to thrive, death at age ~5 
Type V 
Muscle glycogen 
 phosphorylase 
McArdle disease Renal failure 
Type VI 
Liver glycogen  
Phosphorylase 
Her’s disease Growth retardation 
Type VII 
Muscle  
phosphofructokinase 
Tarui’s disease Growth retardation and anemia 
Type IX 
Phosphorylase 
kinase 
 
Delayed motor development and 
growth retardation 
Type XI GLUT2 
Fanconi-Bickel 
Syndrome 
 
Type XII Aldolase A 
Red cell aldolase 
Deficiency 
Exercise intolerance 
 
Table 1. Known glycogen storage diseases and its effects. 
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1. A. Structure of Glycogen 
Glycogen synthesis can be characterized in two basic steps, 
polymerization and branching. Linear polymerization of glucose is catalyzed 
through α-1,4 glycosidic bonds with occasional α-1,6 glycosidic bonds as branch 
points spaced approximately 12-15 glucose residues apart along the linear 
chains (Figure 2B) (1). Glycogen obtained from biological sources is often 
heterogeneous in nature making it an extremely difficult candidate for structure 
determination using classical approaches of structural biology. However, 
extensive chemical analyses had shed light on the overall structure and 
chemistry of glycogen molecules. One widely accepted model (1, 8-11) for 
glycogen structure categorizes the outermost chains of glycogen as A-chains 
which are unbranched and the innermost chains as B-chains which are branched 
and typically contain two branch points per 13 residues. According to this model 
(Figure 2B), glycogen is made up of concentric tiers with the outermost tier 
containing ~50% of the total glucose residues and each tier containing 
approximately twice the number of glucose residues as the preceding one. 
Theoretically,   a maximally sized glycogen molecule will be spherical in shape 
with 12 tiers containing approximately 55,000 glucose residues. Such an 
arrangement not only facilitates maximal storage of glucose molecules, but also 
rapid degradation and release of stored glucose upon depletion. In addition to 
glucose, glycogen also contains trace amounts of glucosamines (12, 13) and 
phosphates (14-16) with the later affecting the branching properties and the 
overall structure of glycogen as seen in the Lafora Disease (17, 18). 
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Figure 2. Structure of glycogen. 
A. Glucose molecule with its carbon atoms numbered from 1-6. B. The tiered 
model showing glycogen molecule as made up of concentric tiers (tiers 1-5 are 
labelled). Glucose polymerization through an α-1,4 glycosidic linkages with 
occasional α-1,6 glycosidic linkage are shown. The G denotes Glycogenin. C. 
Atomic model of CA26 with the inter- and intra-molecular hydrogen bonds are 
shown in dotted lines. D. Glycogen molecule with its linear chains shown as 
helices. The two black circles denote the glycogenin dimer. 
 
Unlike glycogen, amylose is an unbranched form of starch that can be 
crystallized. A crystal structure of cycloamylose (cyclized form of amylose) 
containing 26 glucose residues (CA26) was solved to a maximum resolution of 
A B 
C D 
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1.1 Å (Figure 2C) (19). In this structure, CA26 folds itself into two short left-
handed helices in antiparallel arrangement. Thirteen glucose residues make up a 
helix with 6 glucose residues per turn. Intramolecular hydrogen bonds between 
the hydroxyl groups stabilize the helical structure. Every glycogen chain of 13-15 
glucose residues can be considered to form a helix at which point branching 
occurs and the next helix starts (Figure 2D).                         
1. B. Glycogen synthesis and degradation 
 Glucose metabolism in the skeletal muscle starts with glucose entering the 
cell to be phosphorylated at the sixth position by hexokinase (HK) thus forming 
glucose-6-phosphate (G6P) (20). Once phosphorylated, the metabolic fate of 
G6P depends on the nutritional status of the cell (Figure 3). For instance, when 
nutrients are limiting, the majority of G6P is oxidized through the glycolytic 
pathway or enters the Pentose Phosphate Pathway (PPP) to form NADPH and 
other cellular building materials (21). In times of nutritional sufficiency, excess 
G6P is diverted to form glycogen. Glycogen synthesis (glycogenesis) starts with 
the enzymatic conversion of G6P to an activated nucleotide sugar donor, uridine 
diphosphate glucose (UDP-glucose) (4) . G6P is first converted to glucose-1-
phosphate (G1P) by phospho-glucomutase and then to UDP-glucose by UDP-
glucose pyrophosphorylase. Once UDP-glucose is formed, glycogenin, an auto-
catalytic initiator of glycogen synthesis, transfers glucose to one of its conserved 
tyrosine residues, via a covalent O-glycosidic linkage (22). Glycogenin will 
continue to add an additional 10-12 glucose residues forming a linear chain, 
whereupon glycogen synthase (GS) and the glycogen branching enzyme (GBE) 
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complete the synthesis of glycogen. GS catalyzes the transfer of glucose from 
UDP-glucose to the non-reducing end of the acceptor chain. Glycogen synthase 
is responsible for the bulk of glycogen synthesis and is considered to be the rate 
limiting step in glycogenesis (1). Once the linear chain of glucose exceeds 12 
residues, GBE catalyzes the formation of branches to the growing glycogen 
molecule by transferring 7-8 glucose residues from the terminal chain segment to 
the C6 hydroxyl group of a glucose residue on the same or another chain (1, 23). 
GS will now have two different acceptor chains to which glucose can be added. 
This combined action of both GS and GBE will lead to the synthesis of the 
spherical glycogen molecule.           
        
 
 
 
 
 
 
 
 
 7 
 
Figure 3. Glycogen metabolism. 
Flow chart showing the pathway for glycogen biosynthesis and degradation. 
Synthesis of Glycogen involves Glycogenin, glycogen synthase and branching 
enzyme. Glycogen degradation is mediated by glycogen phosphorylase and 
debranching enzyme. 
 
When the cellular demand for glucose exceeds exogenous supplies, 
glycogen is degraded to mobilize the stored glucose. Glycogen degradation 
(glycogenolysis) requires the combined action of glycogen phosphorylase (GPh) 
and the glycogen debranching enzyme (DBE) (Figure 3). GPh catalyzes the 
phosphorolysis of α-1,4-glycosidic bonds in glycogen(n) producing glucose-1-
phosphate and glycogen(n-1). GPh uses pyridoxal phosphate as a co-factor (24). 
Phosphorylase can act only on linear chains of glycogen (α-1,4-glycosidic bonds) 
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and its action will come to a halt four residues away from an α-1,6-glycosidic 
branch point. To continue the breakdown, the debranching enzyme is necessary 
to remove the branch point. Glycogen debranching enzyme is a relatively large 
enzyme (165kDa) and is composed of two different functional domains with two 
distinct catalytic activities (25). The N-terminal domain of DBE and its associated 
α-1,4-transglycosylase activity will transfer three glucose residues from the four 
residue glycogen branch to the main chain (25). This exposes a single glucose 
residue joined to the main chain through an α-1,6-glycosidic linkage. The C-
terminal domain of DBE will then hydrolyze the α-1,6 linkage  giving free glucose 
as the hydrolysis product (25). 
Reversible synthesis and degradation of glycogen can occur multiple 
times within the cytosol. However, a fraction of glycogen ends up in the lysosome 
where it is irreversibly degraded by a different enzyme, acid-α-glucosidase. 
Glycogen degradation in the lysosome is straight forward. Acid-α-glucosidase is 
capable of hydrolyzing both α-1,4 and α-1,6 glycosidic linkages to produce free 
glucose (26). The importance of this enzyme in glycogen metabolism can be 
seen in patients with Pompe disease where the absence or deficiency of the 
enzyme can lead to abnormal accumulation in lysosomal glycogen with severe 
phenotypes in heart and brain resulting in death within the first year of life 
(https://ghr.nlm.nih.gov/condition/pompe-disease).  
2. Hormonal regulation of glycogen metabolism 
In mammals, skeletal muscle and liver are the two major tissue types 
where glycogen deposits can be found in abundance. The major difference 
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between liver and skeletal muscle glycogen metabolism is the utilization of 
glucose after release from stores. In the fasted state, glucose-1-phosphate 
produced following the phosphorolysis of glycogen is isomerized to form G6P. 
The liver expresses glucose-6-phosphatase, which can dephosphorylate G6P to 
form glucose (27). The free glucose can then be transported into the blood 
stream and on to other tissues, like brain, which depend on glucose as their 
primary energy source. Unlike liver, skeletal muscle does not express glucose-6-
phosphatase and therefore the G6P formed after glycogenolysis is utilized within 
the cell. G6P in the skeletal muscle is used for ATP production during muscle 
contraction by entering into glycolysis. Glycogen metabolism in both liver and 
skeletal muscle is tightly regulated by hormones which are linked to the 
nutritional status of the cell (Figure 4).  
2.  A. Insulin 
Insulin is the primary hormone responsible for signaling the conversion of 
glucose into glycogen. Insulin-stimulated glycogen accumulation accounts for up 
to 30% in liver and 30-90% in the skeletal muscle of postprandial glucose 
disposal (1).  Type II diabetic patients who are insulin resistant often have lower 
levels of liver and skeletal muscle glycogen (28). Insulin promotes glycogen 
accumulation by increasing the activity of GS, the rate-limiting enzyme in 
glycogenesis (29). In the higher eukaryotes, GS activity is regulated by multiple 
mechanisms including covalent modifications, allosteric activation and 
translocations within the cell (4).  The binding of insulin to the extracellular α-
subunit of the insulin receptor activates its tyrosine kinase domain to initiate a 
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series of signaling events that are responsible for activating protein 
phosphatases that dephosphorylate GS and activate the enzyme (30). Insulin 
also stimulates glucose uptake into the cell by translocating glucose transporters 
(GLUT4) to the cell membrane. The glucose is then phosphorylated at the C6 
position by hexokinases to form G6P. As mentioned previously, G6P has multiple 
fates, but is also an allosteric activator of GS, capable of activating GS 
independent of its phosphorylation status (1).  
Rising insulin levels in the liver also inhibit GPh, the rate limiting enzyme 
of glycogenolysis (29). GPh can exist in two different activity states, a more 
active R state and a less active T state depending on the phosphorylation status 
of the enzyme. When phosphorylated (phosphorylase a), the enzyme is activated 
while dephosphorylation (phosphorylase b) inhibits the enzyme, thereby 
demonstrating a reciprocal relationship with GS in terms of regulation (24). AMP 
can activate the enzyme through an allosteric mechanism and shift the 
equilibrium towards a more active R state. Insulin mediated inhibition of GPh 
primarily occurs through glucose binding to phosphorylase. Glucose binding to 
an allosteric site causes a conformational change that makes phosphorylase a 
better substrate for phosphatases. Furthermore, phosphorylase a  is an allosteric 
inhibitor of PP1G/GL, the phosphatase responsible for the dephosphorylation of 
both GS and GPh (29). Glucose mediated conformation change of GPh from 
phosphorylase a to b form relaxes PP1G/GL resulting in the dephosphorylation 
and activation of glycogen synthase (31, 32). 
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Schematic representation of the major players in the regulation of glycogen 
metabolism in the skeletal muscle. The blue open circles are insulin. IR- Insulin 
receptor, AMP- Adenosine monophosphate, AMPK- AMP dependent protein 
kinase, B AR- beta adrenergic receptors, PPP- Pentose phosphate pathway, 
TCA- Tricarboxylic acid cycle, GLUT- Glucose transporters. Red arrows 
represent inhibition while the green arrows denote activation. 
 
2 . B. Glucagon and epinephrine 
  Muscle contraction and epinephrine stimulate glycogenolysis in the 
skeletal muscle while glucagon is responsible for glycogen breakdown in the 
liver. Epinephrine binding to the beta-adrenergic receptor initiates a signaling 
Figure 4. Hormonal regulation of GS. 
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cascade through protein kinase A (PKA) that activates phophorylase kinase 
(PhK) (33). PhK phosphorylates phosphorylase thereby shifting the equilibrium to 
the more active R state, promoting glycogenolysis. Both PhK and PKA can inhibit 
GS by phosphorylating sites on its N-terminus (Biochemistry, Section 21.3). In 
the case of muscle contraction, release of Ca2+ ions from the sarcoplasmic 
reticulum directly activates PhK and thus increases phosphorylation of GPh (34). 
As muscle contraction continues, an increase in the AMP/ATP ratio activates 
AMP kinase that can phosphorylate GPh thereby activating the enzyme. AMP 
itself can activate GPh allosterically, as mentioned previously. In the liver, 
glucagon can activate liver adenyl cyclase which increases cAMP levels which in 
turn activates PKA (https://www.ncbi.nlm.nih.gov/books/NBK22429). The 
activated PKA can phosphorylate both GS and GPh thereby inhibiting and 
activating the enzymes, respectively. 
3. Glycogen metabolism and regulation in yeast 
 Glycogen and trehalose are the two major carbohydrate reserves found in 
yeast. The relative amounts of these macromolecules depend on the changes in 
the environment indicating a complex regulatory system controlling their 
metabolism (35, 36). In the budding yeast Saccharomyces cerevisiae, glycogen 
can account for 20% of its dry weight. Glycogen levels in the cell increase with 
the cell entering the stationary phase and during times of nutritional stress. Yeast 
has two genes for GS, GSY1 and GSY2, the latter being nutritionally regulated 
(37). Yeast Gsy2 enzyme (yGsy2) can be inhibited by phosphorylation and can 
be activated allosterically by G6P. In the yeast cell, Snf1p and PKA are the two 
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kinases responsible for the phosphorylation of GS (Figure 5) (35). Other kinases 
like Pcl8/10p and pho85p are also capable of phosphorylating yGsy2p (38).  
 
Figure 5. Glycogen regulation in yeast. 
Schematic representation of major players in the transcriptional and enzymatic 
regulation of glycogen metabolism in the budding yeast cell.    
 
Unlike other higher eukaryotes, genes involved in yeast glycogen 
metabolism can also be transcriptionally regulated depending on the nutrient 
status of the cell (Figure 5). The activity of the yeast GS enzymes increases as 
the cell enters the stationary phase of growth. The increase is partly due to the 
increase in the level of protein expression rather than a simple change in 
phosphorylation status. This transcriptional regulation of GS and other enzymes 
depend on the stress response element (STRE), cis-element found upstream of 
the promoter of glycogen metabolism genes (35). During times of nutritional 
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sufficiency, the transcriptional activator Msn2/4p is sequestered in the cytosol by 
Bmh1I2p.  Under stress conditions, the trans-activator Msn2/4p dissociates from 
Bmh1I2p and enters the nucleus where it binds to the STRE and increases the 
expression of these genes by 2- to 3-fold. Glycogen degradation and utilization is 
mediated by both c-AMP dependent PKA pathway and a poorly characterized 
PKA independent pathway (38).  
4. Glycogen Synthase 
As previously mentioned, GS is responsible for the bulk synthesis of 
glycogen through formation of α-1,4-glycosidic linkages using UDP-glucose as a 
glucosyl donor to the non-reducing end of an existing glucose polymer (Figure 
6A). Within the glucosyl transferase (GT) super-family, eukaryotic GS is grouped 
into the GTB-fold family of enzymes 
(http://www.cazy.org/GlycosylTransferases.html). The GTB-fold family is 
characterized by the presence of two Rossmann fold domains with a deep inter-
domain cleft where the substrates bind (39). Within the GTB-fold family, 
eukaryotic GS enzyme is further divided into GT3 sub-family because of its ability 
to use UDPG as a donor and its ability to be regulated by covalent 
phosphorylations and allosteric activation (Figure 6B). The bacterial and archaeal 
GS enzymes are grouped into the GT5 family and use ADP-glucose as a donor 
and are not subject to covalent and allosteric regulations (Figure 6B).  
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A.GS catalyzes the transfer of glucose (shown in brown) from UDP-glucose to 
an existing glucose polymer giving away UDP as a bi-product. B. Eukaryotic GS 
is grouped into the GT-3 subfamily of the GT-B fold family of glucosyl-
transferases (GT). 
 
4. A.  Naturally occurring mutation of the glycogen synthase gene 
i. Glycogen storage disease type 0 
  Glycogen storage disease type 0 (GSD0) is a rare autosomal recessive 
disorder caused by deficiency in the liver isoform of glycogen synthase. Patients 
with GSD0 typically experience severe fasting hypoglycemia accompanied by 
hyperketonemia, hyperlipidemia and elevated transaminase levels(40). To date, 
GT-B Fold 
GT-3 Family GT-5 Family 
Animal and Fungal Enzymes 
 
 
Regulation by Phosphorylation 
Allosteric activation G6P 
 
Uses UDP-glucose  
Bacterial and Archaeal  
Enzymes 
 
No Activity Regulation  
 
 
Uses ADP-glucose  
GS 
Figure 6. Enzymatic function and classification of glycogen synthase (GS). 
A 
B 
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sixteen different mutations have been identified in the GSY2 gene that leads to 
GSD0 (Figure 7). Mutations include two splice variants, one deletion mutation, 
four premature stop codons and nine missense mutations (40) (41). Mice lacking 
the GSY2 gene have a 95% reduction in the hepatic glycogen levels and show 
characteristic symptoms similar to the patients with GSD0 (42). 
 
Figure 7. Naturally occurring GS mutations. 
Schematic representation of glycogen synthase gene with exons shown in white 
and the naturally occurring mutants and splice variants that occur in the gene are 
shown in black lines. 
 
Recent studies have shown that mutations in the muscle isoform of GS 
can also lead to glycogen storage defects. Three siblings were identified with a 
premature stop codon at R462 in the GSY1 gene which led to the death of one of 
the siblings following cardiac arrest after a bout of exercise (43). Muscle biopsy 
from the other two siblings showed complete depletion of glycogen, 
predominance of oxidative fibers and mitochondrial proliferation (43). 
ii. Polysaccharide storage myopathy (PSSM) 
 The R309H mutation found in horses leads to a glycogen storage disorder 
characterized by abnormal glycogen accumulation in the skeletal muscle and 
muscle damage with exertion (44, 45). Horses with PSSM show higher GS 
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activity even in the absence of G6P (45). It is the first known loss/gain of function 
mutation in the GSY1 gene leading to glycogenosis. Recent studies have shown 
that mutating the Arg309 to His result in a constitutively active Gsy1 that has 
reduced response to the normally inhibitory phosphorylation events (46). 
5. B. Covalent regulation of eukaryotic glycogen synthase 
 Multiple mechanisms, including covalent modifications, allosteric activation 
and translocations within the cell, regulate the activity of GS. Eukaryotic GS is 
inhibited by phosphorylation. Mammalian GS is one of the earliest examples of a 
multiply phosphorylated enzyme. Earlier studies on the rabbit muscle GS showed 
that the enzyme had 9 discrete sites of phosphorylation: two sites (sites 2, 2a 
which correspond to serines 8 and 11, respectively) on its N-terminus and seven 
sites on its C-terminus (sites 3a, 3b, 3c, 4, 5, 1a and 1b which correspond to the 
serines 641, 645, 649, 653, 657, 698 and 710, respectively) (1). The liver isoform 
GSY2, lacks the extreme C-terminal phosphorylation sites, 1a and 1b. In vitro, 
several protein kinases are capable of phosphorylating subsets of the nine 
different phosphorylation sites. Mammalian GS is also one of a number of 
proteins that shows a hierarchical pattern of phosphorylation where 
phosphorylation of one site primes for the phosphorylation of the next (Figure 8). 
For instance, phosphorylation of site 5 by protein kinase CK2 is recognized by 
GSK3 which then sequentially phosphorylate the sites 4, 3c, 3b and 3a (1). 
Similar pattern of hierarchal phosphorylations can be seen on the N-terminus 
where phosphorylation of site 2 primes for the phosphorylation of site 2a by 
protein kinase CK1 (Figure 8) (1). Elimination of site 2 prevents phosphorylation 
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of site 2a in COS M9 cells (47). Serine  alanine mutagenesis experiments on 
rabbit muscle GS had shown that sites 2, 2a, 3a and 3b (serines 8, 11, 641 and 
645) had the major effect on GS activity (47). Expression of rabbit muscle GS in 
COS M9 cells with the sites Ser641 and Ser645 mutated to alanine resulted in a 
significant increase in glycogen accumulation when compared to the wild type 
GS expressing cells (47). 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. GS regulation by phosphorylation. 
Schematic representation of rabbit GS1 and yeast Gsy2 are shown. The 
phosphorylation sites are shown in black lines and its corresponding serines are 
color coded in red. The grey box represents the arginine cluster. GSK3-Glycogen 
synthase 3  Kinase, CK2- Casein Kinase 2, PKA- Protein kinase A, PhK- 
Phosphorylase kinase. 
 
Dephosphorylating the enzyme can reverse the inhibitory effects of the 
covalent phosphates. Insulin plays an important role in de-phosphorylating both 
637 663 
697 711 
647 676 
CK1 
6 13 
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the N- and C-terminal phosphorylation sites of GS by activating protein 
phosphatases 1 (PP1) (48). The phosphatase action of PP1 is regulated by its 
association with the targeting subunits. There are seven known targeting 
subunits, of which, the following three are widely studied: RGL (49), GL (50), PTG 
(51). The RGL or GM subunit is restricted to skeletal and heart muscle (52) while 
the GL subunit is expressed both in liver and skeletal muscle tissues (53). PTG 
(protein targeting to glycogen) is more ubiquitously expressed and is proposed to 
act as a scaffold protein that can interact with GS, GPh and phosphorylase 
kinase (54).  Mice lacking RGL, which is responsible for recruiting PP1 to 
glycogen in the skeletal muscle, had significantly higher GS phosphorylation 
which was well correlated with decreased glycogen accumulation in these tissues 
(55). Loss of hepatic glycogen binding subunit (GL) in insulin dependent diabetic 
rats led to 70-80% decrease in liver glycogen deposits when compared to the 
wildtype rats (56).    
Since most of the glucose uptake occurs in the skeletal muscle after a 
meal through an insulin dependent process, it is speculated that low glycogen 
levels found in type II diabetes patients are a consequence of inactive forms of 
GS caused by the inability of insulin to signal the dephosphorylation of GS, as 
well as the low influx of glucose to form G6P (57). A second covalent 
modification of GS was recently proposed, an O-linked N-acetyl glucosamine 
attachment which restrains the enzyme in a G6P dependent state and is 
unresponsive to insulin dependent de-phosphorylation (58). Other proteomic 
study identified acetylation of the following lysines in the GS liver isoform: 
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Lys387, Lys397, Lys694 and Lys695 (59). However, the physiological implication 
of these acetylations on GS requires further investigation. 
The yeast GS enzyme lacks the N-terminal phosphorylation sites found in 
the higher eukaryotic enzymes and the hierarchal pattern of phosphorylation, but 
retains the inhibitory effects of C-terminal phosphorylation. There are three 
phosphorylation sites (Ser651, Ser655 and Thr668) on the C-terminal tail of 
yeast Gsy2p (60). When yeast cells express an enzyme truncated at residue 
644, the cells accumulate four times more glycogen then cells expressing the full-
length counterpart (60). In vitro, the Pho85p and Pcl10p complex was shown to 
directly phosphorylate these sites (61). Of the three phosphorylation sites, 
Thr668 has the major effect on the enzyme’s activity. Studies using aspartate 
mutants as surrogates for phosphorylation showed that only the T668D mutant 
decreased the activity of the enzyme despite having no significant effect on the 
activity ratio, suggesting that aspartate mutants do not behave as true phospho-
mimics for the yeast enzyme (61, 62). Phosphorylating the double mutant 
S651A/S655A of yGsy2 with either the Pho85p/Pcl10p or the Pho85p/Pcl8p 
complex drastically decreased the activity, further demonstrating the effect of 
T668 phosphorylation. Recombinant yGsy2p truncated at residue 640 
(yGsy2pΔ640) had an activity ratio of 0.5. However, fusing a 49mer peptide 
containing a phosphorylated T668 to the yGsy2pΔ640 enzyme decreased the 
activity ratio to 0.1 and the activity was restored after treating it with the catalytic 
subunit of the protein phosphatase PP1cγ (63). In vivo, dephosphorylation of 
yGsy2 occurs via a complex comprised of the type-1 protein phosphatase Glc7p 
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and its targeting subunit Gac1p (64, 65). Loss of Gac1p in yeast renders Gsy2p 
inactive and decreases glycogen accumulation in the cells (64). 
4. C. Regulation by Cellular translocations 
Glycogen metabolizing enzymes are also subjected to regulation by 
cellular translocations via an insulin dependent process. GS in skeletal muscle 
and adipocytes is translocated depending on the glucose levels in the cell (66, 
67). Tracking muscle GS in C2L2 and COS1 cells with the help of GFP showed 
that GS is localized near the nucleus when the cellular glucose levels are low 
and is then translocated to the cytosol when the glucose level rises (68). Studies 
in rabbit skeletal muscle have shown that phosphorylation at sites 2, 2a and 1b 
could signal its redistribution within the cell (68). On the other hand, hepatic GS 
remains distributed throughout the cytosol independent of the glucose levels in 
cells, although there is a change from the periphery toward the interior of the 
cytosol as the glucose levels increase within the cell. This translocation of 
hepatic GS correlates with the increase in glycogen deposits which initiate at the 
periphery gradually moving inward (69). 
  The subcellular localization of yeast GS is dependent upon glycogen 
content (70). When glycogen is abundant, Gsy2p-GFP is uniformly distributed 
across the cytoplasm which correlates well with the distribution of the glycogen 
particles. However, under low glycogen conditions, Gsy2p-GFP localizes to 
discrete spots within the cytoplasm. When there is no glycogen, Gsy2p-GFP 
translocate into the nucleus. The results suggest that when the cellular glycogen 
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content is very high, Gsy2p remains anchored to glycogen. However, upon 
glycogen depletion Gsy2p loses this anchor and can traffic into the nucleus. 
6. Allosteric regulation of GS and kinetic model 
The allosteric activator, G6P, can override the inhibitory effects of covalent 
phosphorylation and fully activate GS. In the case of yGsy2p, G6P binding can 
increase the activity of the enzyme by two-fold even when the enzyme is 
dephosphorylated (71). The major kinetic effect of G6P binding to yGsy2p is an 
increase in Vmax rather than on the Km for UDP-glucose (71). However, in the case 
of the mammalian enzymes, G6P binding decreases the Km values for UDPG 
from >30 mM to ~50 µM (72, 73).  
The manner in which G6P and covalent phosphorylation regulates GS is 
controlled by a cluster of six Arginine residues that are conserved across all 
eukaryotes. A scanning mutagenesis study in the yeast enzyme found that 
mutating the first three arginine residues (Arg580, Arg581 and Arg583) to alanine 
resulted in an enzyme that can neither be activated by G6P nor be inhibited by 
phosphorylation (71). Mutating the second set of three arginine residues (Arg587, 
Arg589 and Arg592) rendered the enzyme insensitive to G6P mediated activation 
but allowed it to retain its ability to be inhibited by phosphorylation (71). In the 
rabbit muscle GS, the same set of mutations similarly led to the loss of G6P 
activation but their sensitivity to phosphorylation is swapped such that the N-
terminal triple mutation retained inhibition by phosphorylation (73). 
 Based on these kinetic and mutational studies, a three state conformational 
model was proposed to explain the kinetic behavior of eukaryotic GS (Figure 9) 
 23 
(71). In this model, the enzyme exists in three different states. When the enzyme 
is neither phosphorylated nor bound to G6P, it exists in an intermediate state with 
a Vmax/Km value of ~6. Phosphorylating the enzyme decreases the Vmax/Km ~30-
fold shifting the kinetic equilibrium towards a tense or inhibited state. G6P binding 
to either state will completely activate the enzyme, resulting in a relaxed state 
with maximal activity. G6P binding increases the Vmax/Km value 2.5-fold over the 
intermediate state and more than 50-fold over the inhibited state. 
Phosphorylation of yGsy2 increases the AC50 for G6P by 20-fold from 0.04 mM to 
0.8 mM. 
                   
Figure 9. Three state kinetic model for yGsy2. 
Yeast GS exists in the intermediate state when non-phosphorylated, upon 
phosphorylation the equilibrium shifts towards the highly inhibited tensed state. 
G6P binding can fully activate GS to relaxed state. Figure adapted from J. Biol. 
Chem. 275, 27753-61, (2000).  
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7. Structural studies on eukaryotic glycogen synthase 
  Crystal structures are available only for two eukaryotic glycogen 
synthases, Saccharomyces cerevisiae (63) and Caenorhabditis elegans (74). 
The crystal structure of the yeast GS isoform 2 was solved for both the 
intermediate and G-6-P bound activated state (Figure 10A and 10B). In the case 
of C. elegans, the structure was solved in complex with the C-terminal 34 amino 
acids of human glycogenin (Figure 10C), but the overall structure of CeGS was 
found to be very similar to the basal or the intermediate state of yeast GS (Figure 
10D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 25 
                                                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ribbon representation of the A. basal and B. the activated state of yeast Gsy2. 
Each monomer is color coded. The regulatory helix carrying the arginine cluster 
is shown in cyan. G6P and the sulfate ions are shown in space filling atom 
model. C. Crystal structure of CeGS. The crystal structure of CeGS was solved in 
complex with the 34mer C-terminal tail of human glycogenin (grey). D. Cartoon 
representation of the superposed monomers of Sc GS (green) and Ce GS 
(magenta). Coot was used for super-positioning of both the monomers. 
Both the yeast and C. elegans GS (CeGS) share more than 50% 
sequence identity to its mammalian counterparts (~55% when compared to 
human GS muscle isoform). The major difference between the two species is 
Figure 10. Crystal structures of yeast and Ce GS. 
A B 
C D 
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that CeGS retains the N-terminal phosphorylation sites (sites 2, 2a) while the 
yeast enzyme lacks them (Figure 11). Both species lack the extreme C-terminal 
phosphorylation sites (1a and 1b). GS exists as a tetramer in all the crystal 
structures. Like the other GTB fold family enzymes, each monomer of GS is 
made up of two structural domains: an N-terminal Rossmann fold domain and a 
C-terminal Rossmann fold domain (75). A unique eukaryotic insertion of 
approximately 100 amino acid residues forms most of the inter-subunit 
interactions.      
The regulatory helices containing the cluster of six arginine residues lie at 
the end of the C-terminal domain and are situated anti-parallel to each other 
across one of the molecular 2-fold axes in the tetramer (Figure 10A). It is 
interesting to note that CeGS lacks the last two arginine residues of the cluster 
(Arg589 and Arg592).There is a small insertion of around 13 amino acids on the 
C-terminal domain (from 481-492 in yGSy2p) which provides selectivity to the 
nucleotide donor UDP-glucose for the eukarotic forms rather than ADP-glucose, 
as observed in the bacterial and archael forms.      
  
 
  
2
7
 
           
Figure 11. Multiple sequence alignment of various species of GS.  
The conserved arginines of the arginine cluster are shown in blue and the phosphorylation sites are shown in red. Clustal 
omega was used for alignment and the Genedoc software was used for further manipulations.  
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Glucose-6-phosphate binds to a surface pocket adjacent to the N-terminus 
of the regulatory helix making extensive interactions involving more than one 
subunit (Figure 10B). The 6-phosphate binding pocket is composed of five 
positively charged amino acid residues: His286, Lys290, His500, Arg583 and 
Arg587 (Figure 12A). The last two amino acids are the third and fourth arginine 
residues of the arginine cluster. G6P binding to yGsy2p orders a loop (residues 
from 278 to 284) which was found to be disordered in the basal state structure of 
the yeast enzyme. Binding of G6P and reordering of residues 278-284 is 
associated with large scale translational and rotational movements across the 
regulatory interface.  
The large scale structural transitions associated with G6P binding can be 
better understood if we compare the dimers of the UDP-bound basal state and 
activated state structures (Figure 12B and 12C). In the basal state structure, the 
loop connecting the β-strand 16 and helix α18 are positioned across the 
molecular 2-fold axes and make contact with each other. The α-helix 16 of one 
monomer makes contacts with strand β3 and helix α2 of the opposing monomer. 
Upon G6P binding, the subunit contacts are reformed by a subunit translation of 
more than 15 Å such that α15, α16 and the loop connecting β-strand 16 and α-
helix 18 are no longer at the molecular axes of the dimer and form new 
interactions with α-helices 15 and 16 of the adjacent monomer. These altered 
interactions coupled with a rotational  opening of the N-terminal domain by 4.5º, 
widens the catalytic cleft and affords better acceptor access. The structural 
findings are consistent with the known kinetic properties which showed that G6P 
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binding does not affect the binding of the nucleotide donor while it improves the 
Km for the acceptor by ~50%.   
 
 
 
 
                 
           
             
 
 
A. Cartoon representation of the G6P binding pocket. G6P and the surrounding 
residues with which it interacts are shown in stick model. Ribbon representation 
of a dimer of Sc GS B. in the absence of G6P and C. in the presence of G6P. 
Each monomer is color coded separately and the blue arrows are used to show 
the loss and gain of interaction before and after G6P binding.  
Figure 12. G6P mediated activation of GS. 
A 
B 
C 
Catalytic cleft 
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7.  Role of the regulatory arginines 
 As mentioned previously, the regulatory helices of adjacent monomers lie 
at the end of the C-terminal domain and are situated anti-parallel to each other 
across one of the molecular 2-fold axes in the tetramer. Arg580, Arg583 and 
Arg587 are adjacent to the G6P binding site and make interactions with the 
allosteric activator while the other three arginine residues (Arg581, Arg589 and 
Arg592) lie on the opposing face of the helix and oriented away from the protein 
surface facing the regulatory helix in the opposing subunit. In the basal state 
structure, the regulatory helices are separated by a distance of 8 Å.The binding 
of G6P pushes the regulatory helices apart by an additional 4 Å (Figure 13A and 
13B).  
In order to delineate the role of each of the six arginine residues, mutational 
studies were performed (63). The third and fourth arginine residues of the 
arginine cluster (Arg583 and Arg587) form essential interactions that anchor the 
phosphate of G6P within its binding pocket. Consequently,mutating either one or 
both of the arginine residues to alanine created an enzyme insensitive to G6P 
activation. Mutating the first two arginine residues (Arg580 and Arg581) to 
alanine did not affect the activity of the dephosphorylated enzyme. However 
when Arg580 was mutated to alanine phosphorylation at Thr668 did not fully 
inhibit the enzyme. 
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Figure 13. Role of the regulatory helix. 
Ribbon representation of the regulatory helix of adjacent monomers in the A. 
basal and B. G6P bound activated state of Sc GS. The sulfate and G6P 
molecules are shown in space filling model. The Arg589 and Arg592 of adjacent 
monomers in the basal state structure are position anti parallel to each other. 
 
 Mutating both Arg580 and Arg581 to alanine led to an enzyme whose 
activity ratio was similar with or without phosphorylation (63). Alternatively, 
mutating the arginines 589 and 592 to alanine drastically decreased the basal 
state activity to a level that is similar to the   wild-type enzyme phosphorylated at 
Thr668. However, the double mutant retained its ability to be activated by G6P. 
Therefore, Baskaran et al. (63) proposed that the first two arginine residues of 
the cluster stabilize the enzyme in the inhibited state upon phosphorylation while 
the last two arginine residues keep the enzyme in the basal state. Evidence for 
Arg589 and Arg592 mediated stabilization of the basal state also comes from the 
basal state structure where the two arginines of adjacent monomers were 
positioned across each other. The charge repulsion between the two arginines 
appears to keep the enzyme in the basal state. Mutating the arginines to alanine 
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results in charge neutralization at the regulatory interface and leads to an 
inhibited enzyme. 
8. Donor binding at the catalytic site 
Eukaryotic GS uses UDP-glucose as the activated sugar donor. Along 
with glucose, trace amounts of glucosamine were also found in mammalian 
glycogen (13). Studies demonstrate that rabbit GS was capable of using UDP-
glucosamine as the sugar donor (76). The same study showed that glucosamine 
is incorporated into glycogen at a rate 12-times slower than that for glucose.  GS 
utilization of UDP-galactose/galactosamine, UDP-N-acetyl-glucosamine and 
UDP-xylose as sugar donors is controversial (77-81). However, structural 
information only exists for UDP-glucose in complex with yeast GS. 
The nucleotide donor UDP-glucose binds in a groove along the surface of the C-
terminal Rossmann domain. The positioning of free UDP is unchanged in both 
the basal (63) and activated state structures (82). However, UDP binding in the 
activated state structure differs depending on whether the glucose is also bound 
in the active site (82). The major difference in UDP binding is due to a 
repositioning of the two phosphates in the binding site (Figure 14A and 14B). 
When bound productively for transfer, both the α- and β-phosphates of UDP lie 
parallel to the plane of the glucose residue, in a bent conformation.   However, 
after transfer (UDP product structure), the positioning of the two phosphates 
changes such that the phosphate interaction with the surrounding amino acid 
residues is switched. 
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Ribbon representation of the active site of Sc GS with A. UDP and glucose (pre-
transfer) and B. UDP (post-transfer) only bound structures. The interactions 
made by the ligands with its surrounding amino acid residues are shown in 
dotted lines. C. Superpositioning the monomers of UDP only (magenta) and 
UDP•G (cyan) bound structures. The entire C-terminal domain was used for 
alignment (300-600). The figure was made using Pymol. 
 
In the productive substrate complex (UDP•G bound), the α-phosphate is in 
hydrogen bonding distance to Tyr513 and Thr414 and the β-phosphate interacts 
with the side chains of Lys326 and Arg320. However, in the product transfer, the 
C 
Figure 14. UDP•G binding in yGsy2. 
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α-phosphate that interacts with Lys326 and Arg320 and the β-phosphate is now 
in hydrogen bonding distance to Tyr513 and Thr514. 
The glucose moiety of UDP•G makes several interactions with the 
surrounding amino acid residues (82). In particular, the 6'-OH group of glucose 
interacts with the two highly conserved amino acids His193 and Asn269. The 4'-
OH group is within hydrogen bonding distance to the peptide nitrogen of Gly512 
and one of the phosphate oxygens, while the 3'-OH group interacts with the side 
chains of Trp511 and the highly conserved Glu509. Lastly, the 2'-OH group of 
glucose interacts with the side chains of Arg199 and the β-phosphate of UDP.  
An important feature of glucose binding in the active site is the closure of the N-
terminal domain toward the C-terminal domain. The N-terminal domain of UDP•G 
bound structure is 13.3˚ more closed when compared to the UDP product 
complex (Figure14C).  
9.  Proposed catalytic mechanism 
 There is considerable debate over the chemical mechanism of retaining 
glucose transferases where the stereochemistry of the product anomeric carbon 
is retained with respect to the donor substrate. Both SN2 or SN1/SNi mechanisms 
have proposed for these retaining glucose transferases (82, 83). Mutational 
studies have shown that there is no easily identifiable amino acid in the active 
site of GS that acts as a nucleophile which is a required feature for a SN2 based 
reaction mechanism (82). As a result, the SN1/SNi mechanism is now gaining 
more support (82, 84). According to this mechanism, the β-phosphate of the UDP 
leaving group most likely deprotonates the 4’-OH group of the acceptor so it can 
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serve as a nucleophile and attack the C1 position of glucose, with the 
nucleophilic attack and exit of the UDP leaving group occurring from the same 
face of glucose (Figure 15). This mechanism also requires the formation of an 
oxo-carbenium ion like intermediate. Unlike glycogenin, GS does not use metal 
ions during glucose transfer, and therefore, stabilization of the UDP leaving 
group occurs via hydrogen bond interactions, which include amino acid residues 
Arg199, Arg320 and Lys326 and the helical dipole contributed by residues 513-
521 (Figure 14A).  
 
 
 
 
 
 
SNi mechanism for catalysis. Deprotonation and the nucleophilic attack is 
shown using black headed arrows. 
 
 
 
 
 
 
 
 
 
 
Figure 15. Catalytic mechanism of GS 
 36 
RATIONALE AND OVERVIEW OF THE THESIS RESEARCH 
 The overall aim of this project is to understand the structural basis for the 
regulated inhibition and appropriate substrate selection in the GT3 family of 
enzymes. For this, we will use yeast glycogen synthase as a structural model. 
Yeast GS is ~50% identical to its mammalian counterparts and also shares many 
of the regulatory and catalytic mechanisms of the higher eukaryotic enzymes. 
 Despite structural information on the activated and basal states of yeast 
GS, very little is known about the enzyme’s inhibited state. To gain structural 
insights into the inhibited state, we used the yGsy2-R589A/R592A mutant as a 
surrogate for the phosphorylated enzyme. This double mutant has basal activity 
level similar to the Thr668 phosphorylated enzyme but, at the same time, retains 
the ability to be completely activated by G-6-P. In particular, our laboratory has 
solved the structure of the activated form of this enzyme. Consequently, to 
complete our understanding of the transitions between activity states, we  aim  to 
determine the three dimensional structure of the low-activity state of the 
R589A/R592A double mutant enzyme using X-ray crystallography to define the 
structural features that define the inhibited state.  
 Apart from UDP-glucose, eukaryotic cells also contain other nucleotide-
sugar donors such as UDP-glucosamine, UDP-galactose and UDP-xylose. 
Yeast, in particular, uses these different UDP-sugar donors in the synthesis of its 
cell wall and chitin septum (85). Unlike the yeast cell wall, the structural integrity 
of glycogen has no known functional reason to incorporate different sugars into 
its structure. In addition, glycogen has a well-defined tertiary structure and the 
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addition of a sugar other than glucose can be detrimental to its structure and its 
branching properties. Hence, yGsy2 has to be very selective in choosing the right 
sugar donor as its substrate. In this project, we used X-ray crystallography and 
enzyme kinetics to determine the molecular basis by which yGsy2 discriminates 
between different UDP-sugar donors to be used as substrates by the enzyme.  
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EXPERIMENTAL PROCEDURES 
1. Site directed mutagenesis 
 The wildtype, R589A/R592A and E169Q mutants of yGsy2 in the pET-28a 
expression plasmid were prepared previously by other lab members (63, 71). 
The other mutant constructs (R581A/R592A and R581C/R592C) were created 
from the wildtype sequence using PCR-based site directed mutagenesis 
approach. The following primers were used for amplification for site directed 
mutagenesis (obtained from Integrated DNA Technologies). 
R581C: 
Forward primer: 5’ GTAAAAAAGACAAGATGCCAAAGAATTAATCAAAG3’ 
Reverse primer: 5’CTTTGATTAATTCTTTGGCATCTTGTCTTTTTTAC3’ 
R592C: 
Forward primer: 5’ GAAATAGAACTGAATGCACTGTCCGACTTACTG3’ 
Reverse primer: 5’ CAGTAAGTCGGACAGGCATTCAGTTCTATTTC3’ 
R581A: 
Forward primer: 5’GTAAAAAAGACAAGAGCGCAAAGAATTAATCAAAG3’ 
Reverse primer: 5’ CTTTGATTAATTCTTTGCGCTCTTGTCTTTTTTAC3’ 
R592A: 
Forward primer: 5’ GAAATAGAACTGAAGCAACTGTCCGACTTACTG3’ 
Reverse primer: 5’ CAGTAAGTCGGACAGTGCTTCAGTTCTATTTC3’ 
Pfu Ultra II HS fusion polymerase obtained from Stratagene was used for 
the amplification of the plasmids. The original parental DNA in the amplified 
reaction mix was then digested by Dpn I (New England Biolabs). The Dpn I 
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treated reaction mix was then transformed into DH5-α competent cells. Following 
transformation, a single colony is inoculated into 10mL of LB media containing 50 
µg/mL of Kanamycin and incubated with shaking overnight. The DNA plasmids 
from the colonies were isolated using the Qiagen Miniprep kit (27104). The point 
mutations were confirmed by DNA sequencing of the plasmids either at the DNA 
sequencing core facility of the IU School of Medicine or at Geneseq. 
2. Expression and purification of yGsy2 
 The protein from each yGsy2 construct was expressed and purified as 
described below. The cysteine mutant enzyme was purified similarly but no 
reducing agents were used during purification and storage. The N-terminal His-
tagged yGsy2 constructs (pET-28a) were expressed in E. Coli BL 21 cells. 
Following transformation of the plasmid into BL21 competent cells, a single 
colony was inoculated in 50 mL of LB broth and allowed to grow overnight at 
37°C. The overnight culture was diluted to 6 L using the pre-inoculum and 
allowed to grow at 37° C until an OD600 of 0.6 was reached, at which point, the 
protein expression was induced by the addition of 0.1 mM of IPTG. The cells 
were incubated at 16° C for an additional 16 hours. Cells were collected by 
centrifugation and resuspended in lysis buffer containing 20 mM Tris-HCl, pH 
7.8, 300 mM NaCl, 2 mM Benzamidine, 1 mM β-mercaptoethanol (BME) and 
0.1% Triton X-100. Cells were then lysed by passing three times through the 
micro-fluidizer at 12,000 PSI and the lysate was clarified by ultracentrifugation at 
35,000 rpm for 35 min. The clarified cell lysate was loaded onto a Ni
2+
- 
nitrilotriacetic acid-agarose (Qiagen) column that was pre-equilibrated with lysis 
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buffer. After loading the cell lysate, the column was washed to a baseline 
absorbance using the lysis buffer. Then two separate wash buffers containing 25 
mM and then 50 mM of imidazole in lysis buffer were used to wash the column to 
elute the non-specifically bound proteins. The bound yGsy2 protein was eluted 
with a linear gradient of 50-200 mM imidazole added to lysis buffer. The column 
elution was collected in fractions of 6 mL, and then the fractions were analyzed 
for yGsy2 protein by running on a 10% SDS-PAGE to visualize the protein levels. 
Those fractions that had the desired protein were pooled and dialyzed against 
the Q-Sepharose loading buffer containing 20 mM TRIS-HCl, pH 8.0, 1 mM 
ethylenediaminetetraacetic acid (EDTA), 2 mM benzamidine and 1mM BME. The 
dialyzed sample was loaded onto a Q-Sepharose fast flow (GE Healthcare) 
column which was pre-equilibrated with the loading buffer. The column was 
washed to baseline absorbance with the loading buffer and the bound protein 
was eluted using a linear gradient of 0-1 M NaCl in the loading buffer. The eluted 
fractions were analyzed by running a 10% SDS-PAGE gel and those fractions 
containing >90% yGsy2 was pooled and dialyzed against the buffer containing 20 
mM TRIS-HCl, pH 8.0 and 1mM BME. The dialyzed protein was concentrated to 
a final concentration of 4 mg/mL using the Amicon Centricon-30 centrifugal 
concentration devices. The concentrated protein was then filtered using 
microfuge centrifugal filters, aliquoted to small volumes of 200 µL, flash frozen in 
liquid nitrogen and stored at -80° C.  
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3. Non-reducing SDS PAGE  
In order to demonstrate how disulfide bonding might influence subunit 
associations, the cysteine mutants were analyzed using a non-reducing SDS 
PAGE. The wildtype and yGsy2-R581A/R592A mutant enzymes were used as 
controls. The purified proteins were allowed to pass through an 8% non-reducing 
SDS PAGE gel using standard discontinuous buffer systems. We prepared two 
different samples for each mutant enzyme, one containing 250 mM BME and 
another that lacked BME in the sample treatment buffers. 5 µg of the purified 
recombinant proteins were loaded onto the gel which was developed at 170 V for 
80 minutes and stained with Coomassie brilliant blue R-250. 
4. Gel filtration 
 The purified yGsy2-R581C/R581C mutant was loaded onto the size 
exclusion column; Superpose 6 10/300 GL, at a flow rate of 0.5 ml/min both in 
the presence and absence of 250 mM BME. A solution containing 100 µg each of 
thyroglobulin (669 kDa), ferritin (440 kDa), aldolase (160 kDa), conalbumin 
(73kDa) and ribonuclease (13 kDa) provided molecular weight standards to 
calibrate the column’s elution profile. The apparent molecular weight of yGsy2-
R581C/R592C was calculated from the standard curve obtained from these 
molecular weight standards. 
 
 
 
 
 42 
5. Crystallization 
5.  A.  yGsy2 R589A/R592A mutant 
 Crystallization screening for the yGsy2-R589A/R592A mutant was 
performed using 96-well plates in the Art Robbins, Inc. Gryphon crystallization 
robot. We used commercially available crystal screening solutions from Hampton 
Research and Emerald Biosystems for the screening procedure. The apo 
enzyme and the crystallization solutions were mixed in 1:1 ratio (200 nL each) 
and allowed to equilibrate against 50 µL of the crystallization solution. After 72 
hours, clusters of hexagonal crystals formed in one crystallization condition 
comprising 0.1 M TRIS-HCl, pH 8.0, 200 mM MgCl2 and 20% PEG 8000. This 
particular condition was chosen for further optimization. After several rounds of 
optimization, we found that single diffracting crystals can be obtained only after 
micro-seeding and only in the presence of UDP-glucose. 
The conditions for yGsy2-R589A/R592A were scaled up to 2-3 µL 
volumes and were incubated using the hanging drop vapor diffusion method. The 
protein solution was prepared at 2.5 mg/mL and contained 10 mM UDP-glucose.  
The protein/substrate solution was combined with an equal volume of a 
crystallization reservoir solution composed of 100 mM TRIS-HCl, pH 8.4-8.9, 200 
mM MgCl2, and 5-10% (w/v) PEG 6000. Physically twinned hexagonal crystals 
were obtained in 5-7 days. These crystals were crushed using the seed bead kit 
from Hampton research to form the seed stock solutions. The seed stock 
solutions were made in the mother liquor solution containing 100mM TRIS-HCl, 
pH 8.9, 200 mM MgCl2 and 10% PEG 6000 and serial dilutions of the seed 
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stocks were made in the same mother liquor. Two µL of the protein/substrate 
solution containing 0.2 µL of the seeds were mixed with 2 µL of the reservoir 
solution described above and allowed to equilibrate against the reservoir solution 
at room temperature. Single hexagonal crystals of yGsy2-R589A/R592A 
appeared in about 5-7 days and grew to a maximum length of 200 µm. 
   Prior to data collection, the crystals were cryo-protected by quickly 
transferring them to a fresh reservoir solution to which a final concentration of 
15% (v/v) ethylene glycol had been added. Crystals treated in this manner were 
immediately flash frozen at 100 degrees Kelvin directly in the gaseous nitrogen 
stream for analysis by X-ray diffraction. 
5.  B. UDP-glucose analogues in the activated state 
  The crystal complexes of G6P bound yGsy2 mutants (either 
R589A/R592A or E169Q) and different UDP-sugar donors were obtained using 
the hanging drop vapor diffusion method using previously determined conditions. 
The following UDP-glucose analogues were used for the co-crystallization 
experiment.  
1. UDP-glucosamine (synthesized by Dr. Vimbai M. Chikwana) 
2. UDP-galactose (Sigma, U4500) 
3. UDP-N-acetylglucosamine (Sigma, U4375) 
4. UDP-2-deoxy-2-fluro-glucose (synthesized by Dr. Vimbai M. Chikwana) 
5. UDP-xylose (Carbosynth, MU07658) 
The protein at 2.5 – 3.0 mg/mL was mixed with 25 mM of G-6-P and 10 
mM of the respective UDP-sugar donor. Three µL of the protein/G-6-P/donor 
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complex was then combined with equal volume of the reservoir solution 
containing 100 mM Bis-Tis, pH 6.2-6.5 and 21 – 26 % PEG 300. The 
protein/reservoir mixture was then allowed to equilibrate at room temperature 
against 500 µL of the reservoir solution in a hanging drop set up. Crystals started 
forming after 3 days and grew to a full size of 200 µm after around 3 weeks. The 
crystals were then dehydrated by sequentially transferring the drops in 
increments of 5% to a final reservoir solution containing 30% PEG 300. The 
dehydrated crystals were mounted on to the X-ray machine and frozen at 100 K 
using the gaseous nitrogen stream. 
6. Hydrolysis of UDP-glucose analogues by yGsy2 
In order to test whether the different UDP-sugar donors were hydrolyzed 
by yGsy2, 5 µM of yGsy2 wildtype enzyme containing 1mM G6P was incubated 
with 100 µM of the different UDP-sugars to a final volume of 100 µL.  Fifty µL of 
the reaction mix (t0) was immediately boiled, while the other 50 µL (tO/N) was 
allowed to incubate overnight at room temperature. Following the overnight 
incubation, the reaction mix was boiled to terminate the reaction. Both t0 and tO/N 
samples were then analyzed by high performance anion exchange 
chromatography (HPAEC) using a Dionex ICS3000 system and Chromeleon 
software. All samples were filtered prior to injection. Eluent A consisted of 1 mM 
sodium hydroxide (NaOH), and Eluent B consisted of 1 mM NaOH containing 1 
M sodium acetate (NaOAc). HPLC conditions were based on prior settings (86), 
and a 2x250-mm CarboPac PA1 column (Dionex) was used at a flow rate of 0.25 
ml/min. The elution profile (expressed in terms of percentage of eluent B) was 
 45 
20-50% from 0 to 10 min, 55-85% from 10 to 35 min and 85-100% from 35 to 40 
min with a flow rate of 0.25 ml/min. As a standard, 100 µM UDP and 10 µM of 
UMP were similarly analyzed on the HPAEC column. The hydrolysis products for 
the UDP-sugars were detected by the decrease in the UV peak size of the 
donors and the appearance of a new UV signal corresponding to the standard 
UDP peak. 
7.  X-ray diffraction, data Collection, processing, structure 
determination and refinement 
7.  A.  Data collection 
The yGsy2-R589A/R592A mutant crystal diffraction data were collected at 
the beamline 19-BM operated by the Structural Genomics Consortium located at 
the Argonne National Laboratory. The diffraction data were then indexed, 
integrated and scaled using the HKL 3000 program suite. 
The diffraction data for the G6P bound yGsy2-R589A/R592A and yGsy2-
E169Q co-crystallized with UDP-glucose sugar analogues were collected either 
at the 23-ID or 19-ID beamlines operated by GMCA-CAT and Structural Biology 
Center at the Advanced Photon Source. The data collected were then indexed, 
integrated and scaled using either the HKL 3000 program suite or the XDS auto 
process suite  (87).  
7.  B.  Structure determination, model building and refinement 
The crystal structure of yGsy2-R589A/R592A was solved by the method of 
molecular replacement. The program PHASER MR (88) as implemented in the 
Collaborative Computational Project Number 4 (CCP4) (89) was used for 
 46 
molecular replacement, using a monomer of the basal state yGsy2-
R580A/R581A/R583A (pdb code: 3NAZ) structure as the search model. The 
structural model was refined using REFMAC5 (90), part of CCP4 program 
package. The Britton and H-test for twinning were consistent with merohedral 
twinning with a twin fraction of 0.31. Consequently, all models were refined using 
amplitude-based twin refinement in REFMAC5 as implemented in the CCP4 
program suite. Each refined model was visually inspected and manually adjusted 
using the molecular display program COOT (v0.7.2.1) (91). The ligands UDP and 
UMP were manually docked into the active site using the program COOT and the 
merged models were subjected to further restrained refinements using 
REFMAC5. The monomer libraries for UDP and UMP were obtained from the 
structures previously deposited in RCSB protein data bank (PDB) (pdb codes: 
4KQ1, 4KQM, respectively).  
The different nucleotide bound activated structures of the activated yGsy2-
R589A/R592A enzyme and yGsy2-E169Q were solved by molecular 
replacement using MOLREP as implemented in CCP4 using the G6P bound 
yGsy2-R589A/R592A structure (pdb code: 3NB0) as the search model. The 
refinement program REFMAC5 in CCP4 was used for refining the structural 
models. The monomer libraries for the nucleotides were obtained from the 
previously deposited crystal structures in RCSB PDB. (pdb codes: UDP-N-
acetylglucosamine: 3ST8 ; UDP-xylose: 4WNH; UDP-galactose: 1O0R; UDP-2-
fluoro-2-deoxy-glucose: 1UQT). The monomer library for glucosamine was 
created using the program Sketcher in CCP4. The ligands were manually docked 
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into the active site and after merging the pdb coordinates; the merged structure 
was refined again using REFMAC5. 
8.  Structural alignments and domain motion measurements 
 Different structures of yGsy2 were aligned/superposed using either the 
LSQ superpose feature in the molecular display program COOT or the 
Superpose program, part of the CCP4 program suite. In order to observe the 
overall structural changes between the yGsy2-R589A/R592A inhibited state 
structure and the yGsy2-R580A/R581A/R583A basal state structure, the C-
terminal domains (298-600) of one state were aligned with the corresponding C-
terminal domains of the other state with an additional alignment criterion to fit 
only those atoms of the moving molecule that are in the spherical radius of 30 Å 
centered to the reference molecule using the program Superpose in CCP4. 
The N-terminal domain motions were obtained by superposing the C-
terminal domains of different yGsy2 structures and the rotational matrices 
required to align the corresponding N-terminal domains were obtained from the 
aligned structures. The Protein Domain Motion Analysis program, Dyndom (92), 
was also used to measure the N-terminal domain motions.  
9.  Glycogen synthase activity measurements 
9. A.  Glycogen treatment 
The glycogen used in the GS activity measurements were first treated with 
TMD-8 hydrogen and hydroxide form mixed bed resins (Sigma-Aldrich) to 
remove of any contaminating charged small molecules. The 10-15 mL of the 
TMD-8 resins was washed with 3 column volumes of Milli-Q purified water in a 50 
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mL falcon tube. A freshly prepared sample of 10% rabbit liver Glycogen Type III 
(Sigma-Aldrich) was then mixed with the washed TMD-8 resins and incubated on 
a rotator shaker for 1 hour at room temperature. The resin was then allowed to 
settle down, and the supernatant is collected.  Ice cold ethanol (95%) was added 
to a final concentration of 66% ethanol. In order to facilitate precipitation of 
glycogen, one or two drops of 1M NaCl was added, and the precipitated 
glycogen was collected by centrifugation at 8000 rpm at 4° C for 20 min. The 
precipitated glycogen was resuspended in 95% ethanol and precipitated again 
using the similar centrifugation method. The glycogen pellet was allowed to air 
dry and ground to a fine powder with the help of a mortar and pestle. For small 
quantities of glycogen, the precipitated glycogen was resuspended in 0.5 mL of 
95 % ethanol and dried using a Speed Vac. The glycogen powder was then 
dissolved to 10% w/v with distilled water. 
9. B. Glycogen synthase assays 
i. Standard condition 
 Glycogen Synthase activity was measured using the standard filter paper 
assay as described by Thomas et al (93). The assay quantifies the amount of 
14C-glucose that is incorporated from UDP-14C-glucose into glycogen over a 15 
min time period at 30°C. The standard reaction condition uses 4.44 mM of UDP-
glucose and 6.7 mg/ml of glycogen as near saturating substrate levels. GS 
dilution buffer contains 50 mM TRIS-HCl, pH 8.0, 2 mM EDTA, 0.1% treated 
glycogen and 1 mM DTT. Protein samples were diluted to a final concentration of 
0.02-0.05 mg/mL using the GS dilution buffer. Fifty µL of the reaction mix 
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containing the 14C UDP-glucose, 6.66 mM of cold UDP-glucose and 8 % w/v 
treated glycogen is pre-warmed in a 30°C water bath for 10 min. 25 µL of GS 
sample in the dilution buffer is then mixed with 50 µL of the reaction mix and 
allowed to incubate at 30°C for 15 min. Following the incubation, 65 µL of the 
reaction mix was spotted on the 31-ET chromatographic filter paper. The filter 
papers were washed three times in 66% ethanol with the help of the perforated 
double beaker. The filter papers were then dried under a heat lamp, transferred 
to a vial and filled with scintillation fluid. The 14C counts were measured with a 
scintillation counter. For all the yGsy2 mutants, the activity was measured both in 
the absence and presence 7.2 mM (saturating concentration) of G6P. 
 For the cysteine mutants, the dilution buffer lacked any reducing agents. 
In order to measure the activity in the presence of reducing agents, appropriate 
amounts of DTT/BME/TCEP were added to the reaction mix and the activity 
measurements were done exactly as described above. 
ii. Activity ratio 
Activity ratio is the ratio of the activity of GS in the absence of G-6-P to the 
activity of the enzyme in the presence of saturating amounts of G-6-P. It is a 
surrogate measure for the activity state of the enzyme even though not all 
phosphorylation events affect enzyme activity (1). 
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iii. Reducing agent titrations 
 Three different reducing agents, DTT, BME and TCEP were used for the 
reducing agent titration of the cysteine mutants. Initial stocks of the reducing 
agents were made in degassed water. For these titrations, the activity was 
measured under standard reaction conditions both in the presence and absence 
of G-6-P. The concentrations of the reducing agents were varied in the following 
manner: 1-200 mM BME; 0.1-20 mM DTT and 0.05-5 mM of TCEP. 
iv. G-6-P titrations 
 For the G-6-P titrations, the concentrations of UDP-glucose and glycogen 
were 4.44 mM and 6.67 mg/mL, respectively and the activity was measured in 8 
different concentrations of G-6-P varied in the range of 0.01-10 mM. 
v. UDP-glucose titrations 
 The KM values for UDP-glucose were determined by varying the 
concentration of the donor substrate between 0.05 mM and 6 mM with or without 
saturating amounts of G-6-P. The reaction mix had a fixed concentration of 
glycogen at 6.67 mg/mL. To examine whether BME can affect the KM for UDP-
glucose, a fixed concentration of 200 mM BME was used across different yGsy2 
mutants. 
vi. UDP-sugar donor titrations 
 The activity of yGsy2 wildtype enzyme was measured with varying 
concentrations of nucleotide sugar donors (UDP-FDG, UDP-galactose, UDP-
glucosamine, UDP-GlucNac and UDP-xylose) in the range of 0.01 mM – 20 mM. 
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For this experiment, saturating amounts of G-6-P (7.2mM) and 0.5 mM of UDP-
glucose was used.  
10.  Kinetic data analysis 
 All kinetic data analysis was performed using the program package 
SigmaPlot (version 12.3) by fitting the data to the appropriate binding or kinetic 
equation. The AC50 curves for G-6-P and reducing agents were fit to the four 
parameter logistic equation. The KM values for UDP-glucose were obtained 
following a fit to the standard Michaelis-Menten equation v = Vmax*S/(Km+S) 
where v is the measured reaction velocity, S is the substrate concentration, Vmax 
is the maximum rate achieved by the system and KM is the substrate 
concentration at half maximum velocity. The values presented in this work is the 
average ± the standard error of the mean of three independent experiments 
(n=3). 
 
 
 
 
 
 
 
 
 52 
RESULTS 
1. Expression and purification of yGsy2 
 His-tagged yGsy2R589A/R592A protein was expressed and purified from 
the cell lysates of E. coli BL21-DE3 cells by Ni
2+ 
affinity chromatography followed 
by anion exchange chromatography. The final elute from the Q-Sepharose 
column had more than 90% pure yGsy2 protein as estimated after staining the 
SDS-PAGE gels with Coomasie dye (Figure 16B).  A typical prep of 6 L would 
yield as much as 25-30 mg of protein. There was no significant difference in 
terms of yield per liter for different yGsy2 mutants when compared to the wildtype 
enzyme. As described in the methods, expression and purification of the cysteine 
mutants was done without reducing agents at any point during purification and 
storage. The protein concentration was estimated by the method of Bradford 
using bovine serum albumin as the standard.  
 
 
 
                                                                                                                                    
 
 
 
 
              
Representative SDS PAGE gel of yGsy2-R589A/R592A. A. Ni-NTA column and 
B. Q-Sepharose column purification. 
 
A 
B 
Figure 16. Representative SDS PAGE of ygsy2 purification. 
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2. Crystallization of yGsy2-R589A/R592A 
 The initial crystals of the double mutant were physically twinned (Figure 
17A) and microseeding methods were used to obtain individual crystals. The 
individual crystals formed did not diffract well but the addition of UDP-glucose to 
the protein mix improved the observed diffraction. The crystals diffracted to a 
maximum resolution of 3.6 Å at our home source. The crystals were found to be 
in the trigonal P3221 space group and diffracted to 3.3 Å at the synchrotron 
(Table 2). 
 
 
 
Figure 17. Optimization of yGsy2-R589A/R592A crystals. 
A. Initial physically twinned crystals. B & C. Individual crystals obtained after 
seeding.  
 
The yGsy2-R589A/592A and yGsy2-E169Q co-crystals with both G-6-P 
and UDP-glucose analogues were orthorhombic in shape and diffracted to a 
maximum resolutions between 2.7 – 3.2 Å (Table 2). 
 
 
A C B 
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3. Structure determination and refinement 
 The crystal structure of the yGsy2-R589A/R592A double mutant was 
solved by molecular replacement using the monomer of the yGsy2-
R580A/R581A/R583A triple mutant structure as the search model. Following 
molecular replacement, the appropriate amino acid substitutions were made and 
the structural model was refined using Refmac5 and included NCS restraints for 
each subunit domain combination. The structure was refined to a maximum 
resolution of 3.3 Å with a final Rwork/Rfree of 0.17/0.22. 
 The crystal structures of the G6P bound UDP sugars were solved by 
molecular replacement and the structural models were refined using Refmac5 in 
CCP4 to a final Rwork/Rfree values reported in Table 3. 
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Table 2. Data collection statistics. 
 yGsy2- 
R589A/R592A 
yGsy2-
E169Q+25mM  
G6P+10mM  
UDP-
Glucosamine 
yGsy2-
E169Q+25mM  
G6P+10mM  
UDPFDG 
yGsy2-
E169Q+25mM  
G6P+10mM  
UDP-Galactose 
yGsy2-
E169Q+25mM  
G6P+10mM  
UDP-GlucNac 
yGsy2-
wildtype 
 +25mM  
G6P+10mM  
UDP-Xylose 
 Cell Parameters : 
  
  
 
 
 
Space group 
 Twin fraction 
NA-not applicable 
a =  124.7Å    
b =  124.7Å     
 c =  278.1 Å   
α = 90.00⁰   
β = 90.00⁰        
γ = 120.00⁰  
P 3
2 
2 1  
0.31 
a =  193.04Å    
b =  205.8Å     
 c =  204.6 Å   
α = 90.00⁰   
β = 90.00⁰        
γ = 90.00⁰ 
 I222 
NA 
a =  193.5Å    
b =  206.5Å     
 c =  204.7 Å   
α = 90.00⁰   
β = 90.00⁰        
γ = 90.00⁰ 
 I222 
NA 
a =  193.665Å    
b =  205.099Å     
 c =  206.446 Å   
α = 90.00⁰   
β = 90.00⁰        
γ = 90.00⁰ 
 I222 
NA 
a =  192.53Å    
b =  205.76Å     
 c =  204.44 Å   
α = 90.00⁰   
β = 90.00⁰        
γ = 90.00⁰ 
 I222 
NA 
a =  192.99Å    
b =  204.32Å     
 c =  206.67 Å   
α = 90.00⁰   
β = 90.00⁰        
γ = 90.00⁰ 
 I222 
NA 
DATA COLLECTION STATISTICS  
     
Resolution Range 50.0 - 3.3 Å 145-3.03 Å 145-2.73 Å 145-3.26 Å 145-2.9 Å 145-2.69 Å 
Unique Reflections 
Total Observations 
28283 
1197984 
71743 
307031 
102119 
447683 
63020 
261516 
83598 
169710 
105353 
Completeness 99.4% 95.2% 99.5% 98.3% 98.08% 98.27% 
Redundancy 4.8 (5) 4.27 (1.6) 4.16(4.15) 4.1(3.8) 3.9(3.5) 3.9 (3.4) 
Rpim 0.069(0.306) 0.073 (2.6) 0.072(0.77) 0.061(0.473) 0.038(0.254) 0.033 (0.27) 
CC1/2 0.703 0.997 0.999 0.998 0.999 0.823 
R
merge
 0.134(0.621) 0.079(0.23) 0.05(0.59) 0.072(0.557) 0.108(0.678) 0.093(0.713) 
<I> / sigma
<i>
 10.28 (2.13) 14.7(2.0) 17.8(2.6) 15.3(2.4) 19.2(2.4) 20.14(2.16) 
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Table 3. Refinement statistics. 
REFINEMENT 
STATISTICS 
yGsy2- 
R589A/ 
R592A 
yGsy2-
E169Q+25m
M  
G6P+10mM  
UDP-
Glucosamine 
yGsy2-
E169Q+25mM  
G6P+10mM  
UDPFDG 
yGsy2-
E169Q+25mM  
G6P+10mM  
UDP-Galactose 
yGsy2-
E169Q+25mM  
G6P+10mM  
UDP-GlucNac 
yGsy2-wildtype 
+25mM  
G6P + 10mM  
UDP-Xylose 
Resolution 
Range 
108-3.3Å 145-3.03 Å 145-2.73 Å 145- 3.26 Å 145- 2.90 Å 145- 2.69 Å 
Number of atoms 9846 20685 20555 20719 20780 20712 
R-factors R
work
= 17.5%  
 R
free
 =21.9% 
R
work
= 17.7%  
 R
free
 =25.6% 
R
work
= 19.07%  
 R
free
 =24.9% 
R
work
= 17.53 %  
 R
free
 =25.11 % 
R
work
= 18.43%  
 R
free
 =25.29 % 
R
work
= 19.87%  
 R
free
 =25.92 % 
R.m.s. deviations  
from Ideal 
Values 
Bond angles (°) 
Bond lengths (Å) 
  
  
 
0.007 
1.22 
  
  
 
0.01 
1.515 
  
  
 
0.012 
1.62 
  
  
 
0.010 
1.513 
  
  
 
0.012 
1.649 
  
  
 
0.012 
1.691 
Ramachandran 
Plot 
Preferred/ 
Allowed (%) 
Outliers  (%) 
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4. Overall structure of yGsy2-R589A/R592A 
 The ygsy2-R589A/R592A double mutant enzyme crystallized in the 
trigonal P3221 space group and exhibited diffraction data to a maximum 
resolution of 3.3 Å. The crystals were merohedrally twinned, with a twin fraction 
of 0.31. The asymmetric unit for this crystal form contains a dimer (Figure 18A), 
representing one-half of the functional tetramer (Figure 18B), which is created by 
one of the crystallographic dyads between asymmetric units in the unit cell. The 
structure exhibited defined electron density for residues 2-277; 283-401and 415-
639 in one monomer of the dimer and for residues 2-277; 283-401 and 415-626 
in the other monomer. Both the monomers lacked interpretable electron density 
for the C-terminal 60-70 residues.  
 
 
 
 
 
 
  
5
8
 
 
 
 
 
 
 
 
 
 
   
A. Crystal structure of yGsy2-R589/R592A as seen in the asymmetric unit and B. Ribbon representation of the 
double mutant tetramer using the symmetrical co-ordinates of the dimer as the other dimer. The C-terminal tail of 
each monomer is shown as dotted lines. 
Figure 18. Crystal structure of yGsy2 inhibited state. 
A B 
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The overall structure of the double mutant is very similar to the yGsy2-
R580A/R581A/R583A basal state structure in terms of domain and subunit 
arrangement. As mentioned previously, yGsy2-R589A/R592A like all other yGsy2 
structures contains two structural domains; N-terminal domain comprising 
residues 2-277 and 599-639, and a C-terminal domain comprising residues 283-
598. Both of these structural domains contain a Rossmann fold which in turn is 
characterized by seven beta-sheets flanked by alpha-helices on either side. Most 
of the subunit interactions occur via two long alpha-helices comprising of 
residues 366-430. The regulatory helices containing the cluster of six arginine 
residues lie at the end of the C-terminal domain and are situated anti-parallel to 
each other across one of the molecular 2-fold axes in the tetramer. The 
symmetrical co-ordinates of the crystallographic dyad can be used to assemble 
the biological tetramer.    
Since the double mutant was co-crystallized with UDPG, we found 
electron density for UDP in one subunit (Figure 19A) and UMP in another subunit 
(Figure 19B). Because of the time frame of the crystallization experiment, it is 
highly likely that UDPG was hydrolyzed to form the products UDP and UMP and 
releasing the sugar from the active site (see Figure 29 for more information). The 
interactions made by UDP and UMP with the surrounding amino acids are very 
similar to those previously observed (82). 
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Ribbon representation of A. UDP and B. UMP bound in the catalytic cleft of each 
monomer of yGsy2-R589/R592A. The map shown is the original 2Fo-Fc electron 
density map prior to inclusion of the UDP/UMP in the model contoured at 1.0 
standard deviation of the map. 
 
Since yGsy2-R589A/R592A was crystallized in the absence of G6P, it 
showed the characteristic features of a non-activated yGsy2 enzyme.  Similar to 
the basal state structure, the alpha helices 15 and 16 of one monomer interact 
with β3 and helix α2 of the adjacent monomer thereby hindering substrate 
access to the catalytic cleft (Figure 20A). As previously discussed, G6P binding 
close to the regulatory helix opens up the active site through the translational 
motions of alpha helices 15 and 16 which now interact with the corresponding 
helices of the adjacent monomer (Figure 20B). 
A B 
Figure 19. Nucleotide binding in the active site of yGsy2-R589A/R592A. 
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A. Closed dimer interface of the inhibited state. Ribbon representation of a dimer 
of yGsy2 in the A. inhibited state (ygsy2-R589A/R592A) B. G-6-P bound 
activated state. 
 
 
 
A 
G6P 
Catalytic 
cleft 
Catalytic 
cleft 
B 
Figure 20. Dimer interface of the inhibited and active state of yGsy2. 
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5. Structural comparisons with the basal state structure 
 When compared to the basal state structure, the yGsy2-R589A/R592A 
structure had a more closed tetrameric interface (Figure 22A). In particular, we 
found that the N-terminal domain of the inhibited state structure is more closed 
when compared to the basal state structure. Each monomer of yGsy2 is made up 
of two structural domains: an N-terminal domain where the acceptor is thought to 
bind and a C-terminal domain where the donor binds. Superposing the C-
terminal domain (283-598) of yGsy2-R589A/R592A with both the basal and 
activated state structures showed that the N-terminal domain of the double 
mutant is more closed towards the C-terminal domain when compared to the 
other two structures. When analyzed by the Dyndom program, the N-terminal 
Rossmann-fold domain of the Gsy2-R589A/R592A double mutant structure was 
rotated 5.9° and 10.8° towards a more “closed” domain arrangement compared 
to the basal and activated state structures (Figure 21), respectively. The r.m.s.d 
of N-terminal domain α-carbons and C-terminal domain α-carbons of the yGsy2-
R589A/R592A inhibited state and the yGsy2-R580A/R581A/R583A basal state 
structures are 0.51 and 0.42 Å, respectively, suggestive of a global rigid body 
domain movement. Similar values of 0.62 and 0.71 Å was obtained for the 
inhibited versus the activated state structures again suggesting global rigid body 
domain motions. This N-terminal domain closure observed in the inhibited state 
hinders substrate access, especially the acceptor access to the catalytic cleft 
(Figure 22B). 
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Ribbon representation of the superposed A. basal (blue) and inhibited state (red) 
structures, B. inhibited (red) and activated (green) state structures. The entire C-
terminal domain was used for alignment with the help of CCP4. 
A 
B 
Figure 21. N-terminal domain closure of the inhibited state. 
5.9 ˚ 
C-terminal  domain 
N-terminal domain 
C-terminal  
domain N-terminal domain 
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A. Ribbon representation of the superposed basal (blue) and inhibited (red) state tetramers. The entire C-terminal domain 
of each subunit of the basal state was superposed to the C-terminal domain of the corresponding subunits of the inhibited 
state using CCP4. B. The same figure rotated 90˚ showing the glycogen access to the inhibited state is more closed when 
compared to the basal state. 
Figure 22. Glycogen access to the inhibited state. 
A 
Glycogen access 
Glycogen access 
B 
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These domain motions within the monomer impact the relative positioning 
of the structural elements in the tetramer as well. As mentioned previously, the 
distance between the regulatory helices of adjacent monomers vary depending 
on the activity state of the enzyme. Due to differing residue substitutions and 
differences in the resolution of the structures, we measured the main chain 
distance between residues Asn585 and Arg589 across the regulatory helical 
interface. In the basal state structure, this distance is 12 Å (Figure 23B), while in 
the inhibited state, represented by the Gsy2-R589A/R592A double mutant 
structure, the regulatory helices are 4 Å closer, at a distance of 8 Å (Figure 23A). 
In contrast, the binding of G-6-P pushes the regulatory helices apart, to a 
separation distance of 16 Å (Figure 23C). The structural transitions that impact 
the positioning of the regulatory helices can be communicated to the N-terminal 
domain by the fact that the regulatory helices are directly linked to the N-terminal 
domain by the extension of the helical element composed of residues 600-620 
which lies along the back of the N-terminal domain.  
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A, B and C. Ribbon representation of the regulatory helices of adjacent 
monomers in the yGsy2-R589A/R592A inhibited state, yGsy2-
R580A/R581A/R583A basal state and G-6-P bound wild-type activated state, 
respectively. The Arg589 and Arg592 in the basal state are shown in stick model 
and the bound sulfate ions are shown in space filling atom model. G-6-P (purple) 
bound in the activated state is shown in space filling atoms. 
 
6. Redox regulation of yGsy2 
Based on the changes in distance between the regulatory helices and the 
positioning of symmetry-related residues in the tetramer, we hypothesized that 
we could engineer a reversible redox regulatory feature in the enzyme as a 
surrogate for regulation by phosphorylation through judicious introduction of 
cysteine residues. In the inhibited state structure, arginines 581 and 592 lie 
directly across the dimer interface from each other and their gamma-carbons are 
separated by a distance of 4 Å (Figure 24A). If the activity state of the enzyme is 
directly correlated with this separation distance, we hypothesized that upon 
mutating the two arginines to cysteine residues, the cysteines could form a 
disulfide bond under oxidized conditions and close the distance between the 
A B C 
    Low activity state 
8Å 16Å 
High  activity state 
 
G6P 
G6P 
12Å 
Basal activity state 
R592   R589    
R589   R592   
Figure 23. Regulatory interface of the three states of yGsy2. 
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regulatory helices by an additional 2 Å to generate a fully inhibited enzyme 
(Figure 24B). Importantly, these disulfide bridges can be reduced to release the 
structural constraint and, thus, permit activation.  
 
  
  
 
 
 
 
 
A. Ribbon representation of the regulatory interface in the inhibited state. Each 
monomer is color schemed separately. The arginines 581 and 592 of adjacent 
monomers are showed in ball and stick model. B. Hypothetical representation of 
a disulfide bond being formed between the arginines 581 and 592 of the adjacent 
monomers. 
 
7. Non-reducing SDS-PAGE analysis 
We generated two distinct enzymes with mutations at positions 581 and 
592, Gsy2-R581C/R592C and Gsy2-R581A/R592A.  Both the mutant enzymes 
were purified similar to the wildtype yGsy2 but without any reducing agents. 
When the purified enzymes were examined using a non-reducing SDS-PAGE 
(Figure 25), the cysteine mutants migrated more slowly through the gel when 
compared to their migration upon treatment with 250 mM BME. Judging from the 
 C581     C592 
B 
R581       R592 
4 Å 
R592  R581 
 C592    C581 
Figure 24. Redox regulation of ygsy2. 
A 
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molecular weight standards, the non-reduced yGsy2-R581C/R592C mutant 
enzyme had a molecular weight of >250 kDa, which is consistent with the yGsy2 
tetramer, while the reduced form had a molecular weight of ~72 kDa, which 
isconsistent with the yGsy2 monomer. Both the wildtype and the yGsy2-
R581A/R592A enzyme migrated similar to the reduced form of the yGsy2-
R581C/R592C in the presence or absence of BME.  
 
 
 
 
 
 
 
 
 
 
 
 
SDS PAGE gel showing that the non-reduced yGsy2-R581C/R592C mutant 
migrates as a tetramer while the reduced form migrates as a monomer similar to 
the wild-type and alanine mutants, irrespective of its oxidative status. 
 
 
 
 
 
 
 
Figure 25. Inter-subunit di-sulfide bond formation. 
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8. Gel filtration 
The cysteine mutants with or without 250 mM BME were run through a 
size exclusion column, Superose 6 10/300 GL. The major portion of the protein in 
both the cases eluted at around 15 ml with an apparent molecular weight of 
313.9 kDa as judged from the standards, consistent with a tetramer (Figure 26).  
 
 
 
 
                     
 
 
 
 
 
 
 
Chromatogram showing the elution profile of the yGsy2p-R581C/R592C mutant 
in the presence and absence of 250 mM BME. The major peak at the end of the 
column volume (24 mL) is the UV absorbance pea of β-ME. The inner graph 
shows the standard curve obtained using different molecular weight protein 
standards. 
 
 
Figure 26. Gel filtration analysis of the cysteine mutants. 
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9. Specific activity measurements 
As isolated from E. coli, the specific activity of the yGsy2p-R581C/R592C 
mutant form was decreased 12-fold in the absence of G-6-P and 47-fold in the 
presence of G-6-P when compared to the yGsy2p-R581A/R592A mutant (Table 
4).  In particular, the oxidized form of Gsy2-R581C/R592C had a specific activity 
very similar to the phosphorylated form of Gsy2 and even lower than the Gsy2-
R589A/R592A. In fact, the specific activity of Gsy2p-R581C/R592C is most 
similar to the Gsy2-R589A/R592A enzyme to which the T668 phospho-peptide 
has been ligated (Table 4). Unlike the Gsy2-R581A/R592A enzyme that 
demonstrates a robust activation by G-6-P, the oxidized Gsy2-R581C/R592C 
enzyme cannot be activated by G-6-P at concentrations up to 80 mM.  In contrast 
to the low activity observed for the oxidized form of Gsy2p-R581C/R592C, in the 
presence of 200 mM BME, the enzyme has activity and responses to G-6-P 
almost identical to the control Gsy2p-R581A/R592A mutant enzyme (Table 4). It 
is notable that the activity ratio of yGsy2-R581A/R592A is almost identical to the 
cysteine mutants in the presence of 200 mM BME (Table 4).  
  
 
 
 
 
 
 71 
Table 4. Specific activity measurements. 
Specific activity measurements for different yGsy2 mutants both in the presence 
and absence of G-6-P. 
 Sp Activity  
(µmole/min.mg) 
(-G-6-P) 
Sp activity  
(µmole/min.mg) 
(7.2mM G-6-P) 
Activity ratio  
(-G-6-P/+G-6-
P) 
  1.03±0.03 1.73±0.03 0.6±0.01 
Gsy2-R580A/R581A/R583A* 0.55±0.02 0.51±0.03 1.09±0.02 
Gsy2-R587A/R589A/R592A* 0.38±0.01 0.35±0.02 1.09±0.01 
Gsy2(1-640) +49mer T668P* 0.1±0.01 1.9±0.02 0.05±0.01 
Gsy2-R589A/R592A 0.1±0.01 1.56±0.02 0.11±0.01 
Gsy2-R581C/R592C 0.033±0.001 0.04±0.001 NA 
Gsy2-R581C/R592C 
+200mM BME 
0.58±0.01 2.1±0.02 0.27±0.02 
Gsy2-R581A/R592A 0.41±0.02 1.88±0.04 0.28±0.03 
Gsy2(1-640)-R589A/R592A* 
 + 49mer T668 
0.03±0.01 0.03±0.01 NA 
 
*-Results previously published (63). 
 
10.  Glucose-6-Phosphate titrations 
In the absence of any reducing agents, addition of G6P up to 80 mM did 
not have any effect on the activity of yGsy2-R581C/R592C. However, in the 
presence of 200 mM BME, G6P was capable of activating the enzyme with an 
AC50 value of 0.5 mM (Figure 27). The yGsy2-R581A/R592A mutant can also be 
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activated by G-6-P with an AC50 value of 0.28 mM similar to the cysteine mutants 
in the presence of BME (Figure 27).  
                         
 
 
 
 
 
 
 
Figure 27. G-6-P activation of the yGsy2 mutants. 
G-6-P titration curves for the yGsy2-R581C/R592C mutants both in the presence 
and absence of 200 mM BME. The G-6-P activation curve of yGsy2-
R581A/R592A is shown for comparison. 
 
11.  Reducing agent titrations 
To examine the relationship between reduction and activity in more detail, 
we examined the ability of three reducing agents to activate the Gsy2-
R581C/R592C enzyme, BME, DTT and TCEP. In keeping with the known redox 
properties of the reducing agents, we found that the half-maximal activating 
concentrations (AC50) followed the trend, BME>DTT>TCEP, with AC50 values of 
15.5 mM, 2.5 mM and 0.29 mM, respectively. It is also interesting to note that the 
AC50 values for these reducing agents were similar in the presence of 10 mM G-
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6-P (19.2 mM, 2.3 mM and 0.39 mM for BME , DTT and TCEP, respectively) 
(Figure 28).  
 
 
 
 
 
 
 
 
Dose dependent activation of yGsy2-R581C/R592C with increasing 
concentration of TCEP (red), DTT (green), BME (blue) in the absence of G-6-P. 
B. Activation of yGsy2-R581C/R592C in the presence of G-6-P. The color 
scheme is identical to panel A. 
 
12.  UDPG titrations 
We examined the kinetic parameters for the mutants and, similar to prior 
work, found that the primary kinetic effect was associated with Vmax, with minimal 
effects on KM or S0.5 for G-6-P (Table 5). Using the wild-type Gsy2 enzyme as the 
basis for comparison, the KM values vary less than 3-fold between the mutants 
for any combination of additions (G-6-P or BME), whereas, the Vmax values vary 
between 30- to 50-fold in the absence of G-6-P and/or BME to less than 2-fold 
when both G-6-P and BME are present. For instance, if you compare the Vmax/KM 
values of the wildtype enzyme in the presence and absence of both G-6-P and 
BME, there is a mere 2-fold increase in activity. However, in the case of the 
yGsy2R581,592C (10mM G6P)
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Figure 28. Effect of different reducing agents on the cysteine mutants. 
 74 
cysteine mutants, the increase in activity is ~66 fold with the majority (> 90%) of 
the difference coming from Vmax alone. Interestingly, the AC50 for G-6-P also 
varied by up to 10-fold, with the wild-type Gsy2 having the lowest AC50 at 0.04 
mM and the Gsy2-R581C/R592C enzyme the highest at 0.48 mM. 
Table 5. UDPG kinetics. 
Kinetic parameters for different GSY2 mutants with respect to UDP-glucose (± 
10mM G-6-P) both in the presence or absence of 200mM BME. Data are 
represented as mean ± SEM. 
 
GSY2 
Enzyme 
V
max
  
(-BME, 
 -G-6-P) 
V
max 
 
(-BME, 
+G-6-P) 
V
max
  
(+BME, 
-G-6-P) 
V
max
  
(+G-6-P, 
+BME) 
S
0.5
 
 (G-6-P) 
V
max
/K
M
 
(-BME, 
-G-6-P) 
V
max
/K
M
 
(+BME, 
+G-6-P) 
Wildtype 1.0±0.1 1.7±0.1 0.99±0.1 3.59±0.1 0.04±0.01 1.72±0.05 3.62±0.1 
R589,592A 0.09±0.01 1.8±0.1 0.17±0.006 2.48±0.11 0.29±0.03 0.32±0.06 3.0±0.14 
R581,592C 0.03±0.001 0.04±0.003 0.59±0.02 1.9±0.04 0.48±0.02 0.054±0.001 3.6±0.12 
R581,592A 0.45±0.02 1.8±0.04 0.43±0.007 1.95±0.01 0.1±0.01 0.25±0.03 2.6±0.07 
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13.  Analysis of yGsy2 activity towards different UDP-sugars 
In order to see if yGsy2 hydrolysis activity is limited only to UDP-glucose, 
we incubated different UDP-sugar donors with the wildtype enzyme for 16 hours 
and analyzed the products with the help of a HPAEC column using UV 
absorbance at 262 nm. After overnight incubation, yGsy2 hydrolyzed UDP-
glucose and UDP-glucosamine while the other sugar donors (UDP-galactose, 
UDP-GlucNac and UDP-xylose) were left non-hydrolyzed (Figure 29). From the 
peak area measurements, we found that yGsy2 prefers UDP-glucose over UDP-
glucosamine as a hydrolytic substrate with the former being hydrolyzed 2.5 times 
faster. 
 
 
 
 
 
 
 
 76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Top panel. UV absorbance of the different UDP-glucose analogues after passing 
them through a HPAEC column. Bottom panel. UV absorbance of the same 
sugar donors after 16 hour incubation with yGsy2 in the presence of G-6-P. 
FiguFiFigure 29. Hydrolysis of different UDP-sugar donor. 
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14.  Inhibition of yGsy2 activity by different UDP-sugar donors 
 The activity of yGsy2-wildtype enzyme was measured using the standard 
14C assay in the presence of increasing concentrations of different UDP-glucose 
analogues.  
 
 
 
 
 
 
 
 
 
The yGsy2 wildtype activity was measured in the presence of increasing 
concentrations of different UDP-glucose analogues using the standard 14C 
assay. 
Of all the nucleotide sugar donors, only UDP-FDG and UDP-glucosamine 
were capable of inhibiting the enzyme completely with an IC50 value of 0.27 and 
3.1 mM, respectively (figure 30). UDP-galactose inhibited the enzyme to only 
50% with an IC50 value of 1.2 mM. UDP-GlucNac inhibited the enzyme by less 
than 20% while UDP-xylose up to 20 mM had no significant effect on the 
enzymes activity (Figure 30). 
Figure 30. UDP-sugar donor titrations. 
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15. Substrate binding in yGsy2 active site 
Based on the HPAEC results, the UDP-sugar donors UDP-glucose, UDP-
glucosamine were classified as substrates while UDP-galactose, UDP-N-
acetylglucosamine and UDP-xylose were classified as non-substrates for yGsy2. 
For the sake of simplicity, we have classified UDP-FDG as substrate, since it is a 
non-hydrolysable molecular mimic of UDP-glucose. In order to understand the 
structural basis for substrate vs non-substrate selection in yGsy2, we solved the 
crystal structures of yGsy2 in complex with different UDP-sugar donors to 
resolutions varying between 2.7-3.3 Å in their respective G6P-activated states. 
 In the GT-B fold subfamily of glucosyl transferases, donor binding on the 
C-terminal domain closes the N-terminal domain in order to achieve the 
catalytically competent donor•acceptor complex (39, 82). We used the activated 
state of yGsy2 for these studies because upon G-6-P binding, the tetrameric 
interface of yGsy2 is completely “opened” allowing the individual subunits to form 
the catalytically competent closed conformation of  the N-terminal domain (63). In 
the case of G-6-P bound activated state of yGsy2, the catalytic complex is 
captured by closing the N-terminal domain towards the C-terminal domain by 13˚ 
(82).  
The crystal structure of each nucleotide sugar complex was solved using 
both the wild-type and E169Q mutant (in the presence of G-6-P) and only those 
structures that had complete electron density for both the nucleotide and sugar 
are reported here. The E169Q mutant retains less than 1% of the wild-type 
activity and it has been successfully used to capture the hydrolyzed glucose of 
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UDP•G in the catalytic pocket (82). The overall architecture of the activated 
yGsy2 enzyme is described previously in the G6P bound R589A/R592A mutant 
structure (pdb: 3NB0) (63).  
15.  A. UDP-Glucosamine 
The crystal structure of UDP-glucosamine bound to the catalytic pocket 
was solved using the E169Q mutant. Similar to what was observed for the 
UDP•G complex, only subunit-C of the tetramer showed electron density for both 
UDP and glucosamine while the other 3 subunits had electron density for only 
UDP. Modelling UDP-glucosamine into the observed electron density showed 
that the nucleotide sugar is hydrolyzed (Figure 31). The closest distance between 
the β-phosphate oxygen and the C1 of glucosamine is too long for a covalent 
linkage. A dominant negative peak appeared every time a glycosidic bond was 
modelled and refined, suggesting that the sugar donor is hydrolyzed.  The time 
frame of the crystallization experiment and the absence of an acceptor likely led 
to the non-productive hydrolysis of UDP-glucosamine to UDP and glucosamine. 
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Figure 31. UDP•glucosamine binding to the ygsy2 active site. 
Ribbon representation of UDP and glucosamine bound to the active site of 
yGsy2p E169Q mutant. The map shown is the original 2Fo-Fc map contoured at 
1.0 standard deviation, prior to the inclusion of the ligand in refinement. 
As described in the introduction, the major structural rearrangement 
following substrate binding in the active site is the closing of the N-terminal 
Rossmann fold domain. Structural alignment using the program DynDom 
revealed that the N-terminal domain of the UDP•glucosamine bound subunit is 
13.6 ˚ more closed towards the C-terminal domain when compared to the subunit 
A that had only UDP in its active site (Figure 32). The rmsd  between the aligned 
α-carbons of the isolated N-terminal and C-terminal domains  were 0.48 and 0.78 
Å, respectively, suggestive of a global rigid body domain motion.  
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Figure 32. N-terminal domain closure induced by UDP•glucosamine. 
Ribbon representation of the superposed monomers containing 
UDP•glucosamine (shown in green) and UDP (shown in cyan) in the active site. 
The two subunits were aligned using the entire C-terminal domain (299-600) with 
the help of Superpose program in CCP4. 
  UDP•glucosamine was found to be in a ‘bent’ conformation with the 
diphosphate group of UDP lying parallel to the plane of glucosamine similar to 
the UDP•glucose bound structure (Figure 31 and 33A). The overall interaction 
between yGsy2 and UDP•glucosamine is also very similar to the interaction 
between yGsy2 and UDP•glucose (Figure 33B). The uridine ring is sandwiched 
between the aromatic sidechains of Phe480 and Tyr492. The O4 group of the 
uracil moiety is within hydrogen-bonding distance to the peptide nitrogen of 
Leu481. The 2’- and 3’-OH groups of the ribosyl moiety are in hydrogen bonding 
distance to the sidechain of Glu517. Similar to that observed in the the 
UDP•glucose structure, the di-phosphate of UDP lies parallel to the plane of 
glucosamine, with the α-phosphate within hydrogen bonding distance to the 
13.6 ˚ 
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peptide nitrogen of Tyr513 and the sidechain hydroxyl group of Thr514. The β-
phosphate interacts with the sidechains of Lys326 and Arg320 and the peptide 
nitrogen of Gly23 which lies across the inter-domain cleft.  
 
 
 
 
 
 
                                                                                                   
 
Figure 33. Subunit interactions of UDP•glucosamine. 
A. Superposition of UDP•glucosamine (green) and UDP•glucose (cyan) and the 
surrounding amino acids with which it interacts. B. Subunit interactions made by 
UDP•glucosamine in the active site.     
In the case of glucosamine (Figure 33B), the 6'OH group interacts with the 
side chains of H193 and N269; 4'OH group interacts with the peptide nitrogen of 
G512 and to one of the β-phosphate oxygens; 3'OH group interacts with the 
peptide nitrogen of W511 and the side chain of E509; the 2' amino group 
interacts with the side chain of R199 and the β-phosphate of UDP. 
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15.  B. UDP-2-fluro-2-deoxy-glucose (UDP-FDG) 
 The crystal structure of UDP-FDG in complex with G-6-P bound yGsy2-
E169Q was solved to a maximum resolution of 2.73 Å. Similar to the 
UDP•glucose and UDP•glucosamine structures, only subunit C showed electron 
density for UDP-FDG while the other three subunits exhibited electron density for 
UDP alone. However, modelling of UDP-FDG into the observed electron density 
showed that the nucleotide sugar donor was not hydrolyzed (Figure 34A). 
Structural alignments showed that the N-terminal Rossmann-fold domain of the 
UDP-FDG bound subunit was more closed when compared to the UDP only 
bound subunit (Figure 35). The program Dyndom predicted a 13.2 ˚ domain 
closure and the rmsd between the α-carbons of the isolated N-terminal and C-
terminal domains of the UDP-FDG and UDP bound subunits were found to be 
0.45 and 0.64 Å, respectively, suggestive of a global rigid body domain motion. 
Replacing the 2’-OH group of glucose with a fluorine atom neither affected 
the conformation of the nucleotide sugar nor the interactions within the active 
site. UDP-FDG adopted a ‘bent’ conformation with the diphosphate group of UDP 
lying parallel to the plane of 2-fluoro-2-deoxy-glucose (Figure 34A). The 2’-fluoro 
group interacts with the β-phosphate of UDP and the side chain of Arg199. An 
interesting observation made in this structure is that, next to the 2'-fluoro group is 
a well ordered water molecule (Figure 34A and 34C). The water molecule 
interacts with the 2’-fluorine group of UDP-FDG and the side chain of Arg199. 
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Figure 34. UDP-FDG binding to the yGsy2 active site. 
A. UDP-FDG binding to the active site of yeast GS. The map shown is the 
original 2Fo-Fc map contoured at 1.0 standard deviation, prior to the addition of 
the ligand. B. Superposition of UDP•glucose (green) and UDP-FDG (magenta) as 
seen in the active site. C. Interactions made by UDP-FDG with the surrounding 
aminoacids of the subunit. 
B 
C 
A 
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Ribbon representation of the superposed monomers containing UDP-FDG 
(shown in magenta) and UDP (shown in cyan) in the active site. The two subunits 
were superposed using the entire C-terminal domain (299-600) with the help of 
Superpose program in CCP4. 
 
16.  Non-substrate binding to the yGsy2 active site 
16. A.  UDP-galactose 
The crystal structure of UDP-galactose bound activated yGsy2 was solved 
using both the wildtype and E169Q mutant enzyme. In both the cases, UDP-
galactose was found to be bound very similarly and the subunit architecture was 
also unchanged. However, taking into account the resolution of the structures, 
only the E169Q structure is discussed here. 
 
13.2 ˚ 
Figure 35. N-terminal domain closure induced by UDP-FDG. 
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Figure 36. UDP-galactose binding to the active site. 
Ribbon representation of UDP-galactose bound to the active site of yGsy2p 
E169Q mutant. The map shown is the original 2Fo-Fc map contoured at 1.0 
standard deviation, prior to the addition of the ligand. 
 
The crystal structure of UDP-galactose bound yGsy2-E169Q was solved 
to a maximum resolution of 3.2 Å. UDP-galactose in its non-hydrolyzed form was 
found in all the four subunits. However, only subunit C had complete electron 
density for the ligand and the surrounding amino acid residues (Figure 36). The 
N-terminal domain of the UDP-galactose subunit was 8.5° more closed when 
compared to the UDP bound subunit (Figure 38). 
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Figure 37. Structural conformation and subunit interactions made by UDP-
galactose. 
A. Superposition of UDP-galactose (shown in grey) and UDP-FDG  (shown in 
cyan) as observed in the active site. B. Superposition of UDP-galactose (grey) 
and UDP (green) and C. Interactions made by UDP-galactose with the 
surrounding amino acids of the subunit. 
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Unlike the hydrolysable substrates of yGsy2 which adopted a ‘bent’ 
conformation, UDP-galactose adopted an ‘extended’ conformation (Figure 36 
and 37A). There is no significant change in the conformation of uridine ring of 
UDP-galactose and its interactions with the surrounding amino acids when 
compared to the substrates. The major difference was found to be in the 
conformation of the phosphates and the sugar molecule. The α-phosphate of 
UDP is within hydrogen bonding distance with the peptide nitrogen of Arg320 and 
the side chain of Lys326 while the β-phosphate hydrogen bonds to the peptide 
nitrogen of Gly23. Interestingly, this conformation of UDP in UDP-galactose is 
very similar to the conformation of UDP in UDP only bound monomers (figure 
37B).  
 
 
 
 
 
 
 
 
 
 
Figure 38. N-terminal domain closure induced by UDP-galactose. 
Ribbon representation of the superposed monomers containing UDP-galactose 
(shown in grey) and UDP (shown in cyan) in the active site. The two subunits 
were superposed using the entire C-terminal domain (299-600) with the help of 
superpose program in CCP4. 
8.5 ˚ 
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In the case of galactose (Figure 37C), the 6'-OH group is essentially free 
without making any subunit interactions. The 3'- and 4'- OH groups are within 
hydrogen bonding distance to the side chain of Arg199 and the 2’-OH group of 
galactose interacts with the side chains of Arg 320 and Lys326.  
16. B.  UDP-N-acetylglucosamine (UDP-GlucNac) 
 The crystal structure of UDP-GlucNac bound activated yGsy2 was solved 
using both the wildtype and E169Q mutant enzyme. In both the cases, UDP-
GlucNac was found to be bound very similarly and the subunit architecture was 
also unchanged. For consistency purposes and also taking into account the 
resolution of the two structures, the crystal structure of the yGsy2-E169Q mutant 
is discussed here. 
The yGsy2-E169Q.G6P complex co-crystallized with UDP-GlucNac 
diffracted to a maximum resolution of 2.9 Å. The structure showed electron 
density for UDP-GlucNac in its non-hydrolyzed form in subunits B and D while 
subunits A and C either had no or incomplete electron density for the sugar 
molecule. UDP-GlucNac adopted an ‘extended’ conformation similar to UDP-
galactose (Figure 39A). The majority of the subunit interactions come from the 
UDP group with the N-acetylglucosamine group making minimal contact with the 
surrounding amino acids (Figure 39B).  The subunit interactions of the UDP 
moiety are essentially the same as the UDP group of UDP-galactose. In the case 
of N-acetylglucosamine, the following interactions were observed: the 3'-OH 
group is in hydrogen bonding distance to the peptide nitrogen of Gly23; the 6'-OH 
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interacts with the peptide nitrogens of Trp511 and Gly512 and the oxygen atom 
of the acetyl group interacts with the side chain of Arg20 (Figure 39B).                   
                             
 
 
 
 
 
               
 
Figure 39. UDP-GlucNac binding to the active site. 
A. Ribbon representation of UDP-GlucNac bound to the active site of yGsy2p 
E169Q mutant. The map shown is the original 2Fo-Fc map contoured at 1.0 
standard deviation, prior to the addition of the ligand. B. Stick representation of 
UDP-GlucNac and its interacting amino acids in the active site of yGsy2p. C. 
Superposition of UDP-GlucNac (blue) and UDP-FDG (magenta) as observed in 
the active site. 
A 
Y492 F480 
E517 
G23 R320 
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Because of the relatively minimal interactions with the surrounding amino 
acids, N-acetylglucosamine was not able to close the N-terminal domain (Figure 
40). In fact, UDP-N-acetylglucosamine binding to the active site further opened 
the N-terminal domain of yGsy2. The domain motions were quantified using the 
program Dyndom and it showed that the N-terminal domain of the UDP-GlucNac 
bound subunit is 6.5˚ more open when compared to the UDP only bound subunit 
(Figure 40). 
  
Figure 40. N-terminal domain motions induced by UDP-GlucNac. 
Ribbon representation of the superposed monomers containing UDP-GlucNac 
(shown in blue) and UDP (shown in cyan) in the active site. The two subunits 
were superposed using the entire C-terminal domain (299-600) with the help of 
the program superpose in CCP4. 
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16. C.  UDP-Xylose 
 The crystal structure of UDP-xylose bound G-6-P activated wt-yGsy2 was 
solved to a maximum resolution of 2.69 Å. Of the four subunits, we observed 
electron density for UDP-xylose in subunits B and C while subunits A and D had 
an incomplete electron density for the sugar molecule. UDP-xylose adopted an 
‘extended’ conformation similar to UDP-galactose and UDP-GlucNac (Figure 41). 
In subunit C, apart from UDP-xylose, we also found electron density for two 
water molecules on either side of the 2’-OH group that seems to bridge the ligand 
interaction with the protein molecule (Figure 42A). 
                    
Figure 41. UDP-xylose binding to the yGsy2 active site. 
Ribbon representation of UDP-xylose bound to the active site of yGsy2p. The 
map shown is the original 2Fo-Fc map contoured at 1.0 standard deviation, prior 
to the addition of the ligand.  
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The uridine interactions found in UDP-xylose are very similar to the other 
structures. The α-phosphate of UDP is in hydrogen bonding distance to the 
sidechain and peptide nitrogen of Arg320 while the β-phosphate oxygen 
hydrogen bonds to the peptide nitrogen of Gly23. The 2'-OH of xylose is within 
hydrogen bonding distance to the two water molecules and these water 
molecules in turn interact with the peptide nitrogen of Trp511 and the side chains 
of Glu509 and Lys326. In addition to these water mediated interactions with the 
subunit, the 2' and 3'-OH groups of xylose also interacts directly with the 
sidechain of Arg199. The 4'-OH group and the 5'-oxygen of xylose are within 
hydrogen bonding distance to the sidechains of Gly23 and Arg320, respectively 
(Figure 42A). When compared to the UDP only bound subunit, the N-terminal 
domain of UDP-xylose subunit was only 8.6˚ more closed towards the C-terminal 
domain.  
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A. Stick representation of UDP-xylose and the surrounding amino acids with 
which it interacts. B. Superposition of UDP-xylose (gold) and UDP-FDG 
(magenta) as observed in the active site. C. Superposition of yGsy2 monomers 
containing UDP-xylose (shown in gold) and UDP (shown in cyan) in the active 
site. The two monomers were aligned using the entire C-terminal domain (299-
600) using the program in CCP4. 
C 
8.5 ˚ 
Figure 42. Subunit interactions made by UDP-xylose and the domain 
motions induced by it. 
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DISCUSSION 
 Multimeric oligomerization and domain motions provide eukaryotic GS 
with multiple levels of regulation. Since yGsy2 shares many of the regulatory and 
catalytic mechanisms with its mammalian counterparts, the yeast enzyme has 
been extensively studied over the years. Despite a wealth of information on the 
kinetic and structural functioning of yGsy2, certain key questions remain 
unanswered.  The crystal structures obtained from this work will shed light on the 
mechanism of substrate selection and regulated inhibition in yeast GS which can 
be extrapolated to other eukaryotic forms based on their sequence identity and 
structural homology.  
1. Substrate selection in yeast Gsy2 
Eukaryotic GS enzymes are grouped into the GT3 family of glucosyl-
transferases because of their preference for UDP-glucose as its sugar donor 
substrate. In addition to UDP-glucose, a eukaryotic cell also contains significant 
amounts of other nucleotide sugars such as UDP-galactose, UDP-GlucNac, and 
UDP-xylose. Yeast, in particular, uses these sugar donors to synthesize its cell 
wall and chitin septum (94). The yeast cell wall is comprised of different sugar 
moieties like glucose, mannose, galactose and GlucNac while chitin is 
synthesized exclusively using GlucNac (85, 94). Unlike the yeast cell wall, the 
incorporation of other sugar residues could be detrimental to the structure of 
glycogen. Previous crystallographic studies have shown that long polymers of 
glucose are helical and the intra and inter-molecular hydrogen bonding between 
the hydroxyl groups of glucose stabilize its helical structure (19). Since glycogen 
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is made of many such chains of glucose, it is highly likely that glycogen shares 
similar structural properties. Erroneous addition of an alternative sugar residue 
that cannot adopt a similar hydrogen bonding pattern into a growing glycogen 
polymer could adversely affect the three dimensional structure of glycogen.  
That GS needs to be very selective in choosing the UDP-sugar donors 
can be best explained if we look into the impact that different sugar molecules 
would have on the structure of glycogen and/or the process of catalysis. 
Galactose incorporation into glycogen might not affect the glycogen structure 
significantly but it is highly likely to act as a chain terminator.  Placing galactose 
on the non-reducing end of glycogen will leave an incoming acceptor with the 4’-
OH group positioned axially where it will impact formation of the α-1,4-glycosidic 
bond either because it could not be properly activated for attack or the new 
stereochemistry of such a glucosyl-galactosyl bond would prevent the resulting 
acceptor from being productively positioned in the active site, in either case it 
would result in terminating glycogen chain extension.  
On the other hand, GlucNac and xylose additions into glycogen is likely to 
affect its structure as both lack an OH group required to form the hydrogen bonds 
that stabilize the helical structure of glycogen. In addition to the detrimental effect 
xylose can have on the glycogen structure, it can also affect its branching 
properties. Every time xylose is added into glycogen, it loses a potential branch 
point. Excessive addition of xylose could result in a glycogen molecule with fewer 
branches and can lead to the formation of long insoluble polysaccharides.             
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To identify the mechanism by which yGsy2 discriminates substrates from 
non-substrates, we performed HPAEC analysis, X-ray crystallographic and 
kinetic studies on different UDP-sugar donors.  
 
 
 
 
 
Figure 43. Analysis of glucose and its analogues as potential substrates. 
 
 Our HPAEC studies demonstrated that only UDP-glucose and UDP-
glucosamine can be captured in the active site of yGsy2 and transferred to water. 
The ability to utilize UDP-glucosamine is not completely surprising because trace 
amounts of glucosamine have been detected in glycogen (12, 13). Most 
importantly, previous studies have also demonstrated that rats can incorporate 
14C-labelled glucosamine into liver glycogen (76). Our crystallographic studies 
revealed that UDP-glucosamine adopts a “bent” conformation in the active site 
similar to UDP-glucose and in both cases, the N-terminal domain was completely 
closed towards the C-terminal domain. Chemically, glucosamine is very similar to 
glucose but has an amine group on its second carbon instead of the OH group 
(Figure 44). Both the 2’-amine and -hydroxyl groups are capable of acting as 
hydrogen bond donors. Therefore, glucosamine incorporation into glycogen is 
unlikely to affect the hydrogen bonding patterns of the glucose polymer to a large 
(GlucNac) (Gal) (Gln) 
(FDG) 
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extent. However, yGsy2 transfers UDP-glucosamine to water at a slower rate, 
compared to UDP-glucose, and animal studies demonstrated glucosamine was 
incorporated into glycogen at a rate one tenth that of glucose (76).  The physical 
basis for the slower rates associated with glucosamine catalysis are less clear, 
since the active site hydrogen bonding patterns are very similar between the two 
sugars.  However, if the amine group of glucosamine is charged in the active site, 
it is possible that stronger interactions with both Glu509 and the beta-phosphate 
of UDP could slow product release or the charge neutralization of the beta-
phosphate could slow the deprotonation of the incoming 4’-OH of the acceptor 
molecule. 
Unlike UDP-glucose and UDP-glucosamine, yGsy2 did not hydrolyze 
UDP-galactose, UDP-xylose or UDP-GlucNac nor do chemical analyses of 
glycogen detect significant incorporation of these sugars. X-ray crystallographic 
studies showed that these non-substrates adopted a “stretched” conformation 
within the active site of yGsy2 and the N-terminal domains did not close down 
and capture the nucleotide sugars for productive transfer.  
A common feature of the non-productive complexes with the non-
substrate sugars, were interactions between the sugars and Gly23.  These 
interactions do not occur when glucose or glucosamine are productively bound 
because the main chain nitrogen of Gly23 interacts with the UDP pyrophosphate 
oxygens.  Thus, the non-substrates prevent catalytic closure of the N-terminal 
domain by engaging Gly23 across the inter-domain cleft and preventing the N-
terminal domain from closing further such that Gly23 can bind to the UDP moiety. 
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In addition to this, the non-substrates also lose interactions with one or more of 
the N-terminal domain amino-acid residues with which the substrates interact 
(Arg199, His193 and Asn269).  
Galactose is a C-4 epimer of glucose (Figure 43). The chiral configuration 
of the 4'-OH group is switched between the two sugar molecules. The 4'-OH 
group of glucose lies in an equatorial position while in galactose, it is positioned 
axially (Figure 43). Because of the difference in stereochemistry of the two sugar 
molecules, the 4'-OH group of galactose is loses two important hydrogen bonds 
that stabilize the “folded” conformation of UDP-glucose in the yGsy2 active site 
(Figure 44A). The inability of the 4’-OH to productively engage G512 and the 
alpha-phosphate of UDP results in the sugar adopting the stretched conformation 
in the active site of yGsy2 where it also fails to interact with residues His193 and 
Asn269 on the surface of the N-terminal domain across the catalytic cleft (Figure 
44B) and instead forms interactions with Gly23, which blocks the ability of the 
domain cleft to close down upon the nucleotide sugar complex.  
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A. Stick representation of galactose (cyan) superposed on glucose (green) in the 
UDP•G bound structure. The dotted lines represent the hydrogen bonds made by 
4'-OH group of glucose with the peptide nitrogen of Gly512 and the α-phosphate 
oxygen of UDP. B. Stick representation of the superposed UDP-galactose (grey) 
and UDP-FDG (magenta) bound structures. The black circle shows the loss of 
interactions between galactose and the sidechains of His193 and Asn269. The 
entire C-terminal domain was used for aligning the two structures with the help of 
CCP4. 
Similar to that observed for UDP-Gal, GlucNac (Figure 43) loses all of the 
interactions made by glucose with the N-terminal domain as a consequence of 
the 2’-N-acetylamine in its structure (Figure 45B). When the structure of GlucNac 
is superimposed on the glucose bound structure, the larger N-acetylamine group 
is likely to sterically hinder interactions with the sidechains of Arg199 and Arg320 
if bound in a “bent” conformation (Figure 45A) and also possibly interfere with 
A                              B                    
N269 
H193 
R199 
G23 
G512 
Figure 44. Structural basis for the observed UDP-galactose conformation in 
the active site of yGsy2. 
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acceptor binding. As a result, it adopts a more favorable linear/stretched 
conformation with minimal subunit interactions and domain motions. 
  
 
 
 
 
 
 
 
 
Figure 45. Structural basis for the observed UDP-GlucNac conformation in 
the active site of yGsy2. 
A. Stick representation of UDP-GlucNac (blue) with a bent conformation placed 
in the active site of the UDP•G bound subunit. The red circle shows the steric 
hindrance created by the side chains of Arg199 and Arg320. B. Stick 
representation of the superposed UDP-GlucNac (blue) and UDP-FDG (magenta) 
bound structures. The black circles show the loss of interactions between 
GlucNac and the sidechains of His193, Arg199 and Asn269. The entire C-
terminal domain was used for aligning the two structures with the help of CCP4. 
 
Unlike galactose and GlucNac, where there are additions or epimeric 
changes to existing sugar ring substituents, xylose completely lacks the 6'-OH 
group (Figure 43). In glycogen synthase, the 6'-OH group of glucose hydrogen 
bonds with the side chains of His193 and Asn269 thereby helps to stabilize the 
A                              B                             
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catalytic productive bent conformation of UDP•G (Figure 46A). Since xylose lacks 
the 6'-OH group, these interactions cannot be made and likely reduces the 
stability of the closed N-terminal domain conformation necessary for productive 
transfer of the sugar.  
 
 
 
 
 
 
       
 
  
A. Stick representation of UDP•G (green) bound in the active site of yGsy2.The 
dotted lines represent the hydrogen bonding interactions made by the 6’-OH 
group of glucose with the sidechains of His193 and Asn269. B. Stick 
representation of the superposed UDP-xylose (gold) and UDP-FDG (magenta) 
bound structures. The black circle shows the loss of interactions between xylose 
and the sidechains of His193 and Asn269. The entire C-terminal domain was 
used for aligning the two structures with the help of CCP4. 
  
 
 
A                                B                             
Figure 46. Structural basis for the observed UDP-Xylose conformation in 
the active site of yGsy2. 
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2. Catalytic mechanism of yGsy2 
Recent crystallographic studies on different retaining type glucosyl-
transferases including yGsy2 had shown that these enzymes are likely to use an 
internal nucleophilic substitution (SNi) mechanism for catalysis (39, 82, 84). 
According to this mechanism, the β-phosphate of the UDP leaving group will 
likely deprotonate the 4'-OH group of the acceptor and the subsequent 
nucleophilic attack will likely occur from the same face as the departing leaving 
group. This mechanism also requires the formation of an oxo-carbenium ion-like 
intermediate state. So far, crystal structures are available only for the hydrolyzed 
form of UDP•G bound to the active site and only in the absence of an acceptor 
(82). We used UDP-FDG as a non-hydrolysable UDPG analogue in the hopes of 
capturing the donor in its non-hydrolyzed state. The fluorine at the 2'-position 
inductively destabilizes the oxo-carbenium ion-like transition state thereby 
slowing the reaction dramatically (95). It has been successfully used in several 
cases as a substitute for UDP-glucose and UDP-galactose (95, 96).  
 Our crystallization experiment captured UDP-FDG in its non-hydrolyzed 
form where it adopts a “bent” conformation similar to UDP•G (Figure 47A). UDP-
FDG also made subunit interactions similar to UDP•G showing that the sugar 
donor is likely to exist in a single conformation before and after hydrolysis. The 
water molecule observed next to the 2-fluoro-2-deoxy-glucose (Figure 47A) is 
positioned in such a way that is likely to act as a nucleophile in the absence of 
the glycogen acceptor (Figure 47B). Based on these observations, we propose 
that the 4'-OH group of the incoming glycogen acceptor is likely to position itself 
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analogous to the water molecule and proceed with the catalytic reaction as 
described previously. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 47. Molecular basis for UDP-glucose hydrolysis. 
A. Stick representation of UDP-FDG bound in the active site of yGsy2. The map 
shown is the original 2Fo-Fc electron density map contoured at 1.0 standard 
deviation, prior to the additional of the ligand and water molecule. The water 
molecule (blue) is shown in sphere model. B. Proposed catalytic mechanism for 
UDP•G hydrolysis using water as an acceptor.  
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The crystal structure of E. coli GS was solved in both the apo-form (pdb 
code: 3D1J) and in the donor•acceptor complex form (pdb code: 2R4T) using 
ADP-glucose as the donor and HEPPSO as an acceptor analogue (39). It was 
found that in the donor•acceptor complex structure, the N-terminal domain was 
14.5 ˚ more closed when compared to the apo structure thereby trapping the 
donor and acceptor in a catalytically competent conformation. It was also found 
in these structures that the acceptor analogue enters the catalytic cleft by binding 
along the surface of the N-terminal domain. Similarly, the N-terminal domain 
closure induced by UDP-glucose and UDP-glucosamine in yeast Gsy2 is likely to 
bring the 4'-OH group of the acceptor in proximity to the donor-sugar thereby 
trapping the enzyme in a catalytically competent donor•acceptor complex for 
efficient sugar transfer (Figure 48A, 48B).  
The non-substrates on the other hand are not likely to achieve the 
catalytically active complex as they adopted a “stretched” conformation that 
restricted the N-terminal domain closure no greater than 8.5˚ (Figure 48A). In 
addition, the position of the C1-carbon and the diphosphate of UDP are less 
conducive for nucleophilic attack. Our kinetic studies also showed that unlike the 
substrates, the non-substrates were not capable of completely inhibiting the 
enzyme’s ability to use 14C-labelled UDP-glucose as the donor (Figure 30). 
Taken together, we propose that GS will selectively eliminate UDP-sugars other 
than UDP-glucose and UDP-glucosamine from remaining in the catalytic cleft as 
they cannot be catalytically captured in the active site without the ability to induce 
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active site closure. Without the ability to induce stable closure of the active site, 
productive transfer to the glycogen is also unlikely. 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. Ribbon representation of the superposed monomers of the G6P bound yGsy2 
containing UDP•G (yellow), UDP•glucosamine (green), UDP-FDG (magenta) and 
UDP (cyan) in its active site.  Hypothetical cartoon representation of the 
donor•acceptor complex when B. substrates and C. non-substrates are bound in 
the catalytic cleft of yGsy2. A monomer of yGsy2 is shown with the C-terminal 
domain colored green and the N-terminal domain in brown. The N-terminal 
domain motion following substrate binding on the C-terminal domain is indicated 
using an arrow. 
 
N-terminal domain C-terminal domain 
13.3 
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Figure 48. Catalytic role of N-terminal domain closure. 
C 
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3. Role of the regulatory helix in the inhibition of GS 
Allosteric and covalent regulation of glycogen synthase allows the enzyme 
to exist in different conformational states. Based on the kinetic studies, a three 
state model was proposed for yGsy2 (71). Dephosphorylated yGsy2 in the 
absence of G-6-P had an intermediate basal activity state. Phosphorylation of the 
enzyme inhibits its activity to a low level - the tense state - while addition of G-6-
P either to the phosphorylated form or to the dephosphorylated form activated 
the enzyme to a high activity, or relaxed state. Until this study, structural 
information was available only for the basal and activated states of the enzyme 
(63). The nature of the inhibited state was an extrapolation from the two known 
structural models that was supported by kinetic and mutational studies. 
Phosphorylation of yGsy2 occurs outside of the catalytic core (residues 1-
620) on the C-terminal tail. Among the three phosphorylation sites, T668 has the 
dominant inhibitory effect on the enzyme activity (63, 71). Substituting arginines 
589 and 592 of yGsy2 with alanine resulted in an enzyme that had a basal 
activity similar to that of the T668 phosphorylated enzyme. However, this mutant 
enzyme still retains the ability to be fully activated by G-6-P. It is interesting that 
while the yGsy2-R589A/R592A enzyme can be fully activated by G-6-P, when 
phosphorylated on T668, the yGsy2-R589A/R592A enzyme can no longer be 
activated by G-6-P at concentrations up to 10 mM.  
  In order to gain insight into the structural characteristics of the inhibited 
state of GS, we solved the crystal structure of the low activity yGsy2-
R589A/R592A enzyme as a surrogate for the phosphorylated form. Despite 
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sharing the overall oligomeric arrangement with the basal state enzyme, the 
double mutant demonstrated additional rotational closure of the N-terminal 
Rossmann-fold domain which was correlated with decreased separation between 
the regulatory helices of adjacent monomers. These motions created a more 
compact tetrameric interface than in the basal state. Based on these 
observations, we propose that the electrostatic repulsion between the opposing 
arginine residues on the regulatory helix keeps the enzyme “spring-loaded” in the 
basal state, so it can respond to regulatory inputs more effectively. Supporting 
this hypothesis is one of our basal state structures where an alternate 
conformation was observed when a sulfate induced a collapse of the regulatory 
helices and a more compact interface (pdb code: 3NCH) (Figure 49) (63). Thus, 
charge neutralization either by mutating the arginines to alanine or through anion 
binding (sulfate or phosphate) collapses the regulatory helices and induces 
further tightening of the inter-subunit interfaces.  
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Figure 49. Role of the regulatory interface in inhibiting GS. 
Ribbon representation of the superposed yGsy2-R589A/R592A (red) inhibited 
state structure and the basal state structure (cyan) with a sulfate bound on its 
regulatory interface. The arginines 589 and 592 are shown in stick model and the 
sulfate is shown in space filling atom model. 
Unlike the yeast enzyme, Caenorhabditis elegans GS (CeGS) contains 
the N-terminal phosphorylation sites (sites 2 and 2a) similar to the mammalian 
enzymes but lacks the last two arginine residues of the arginine cluster. The 
structure of CeGS showed that the N-terminal phospho-sites are positioned in 
such a way that it can interact with the regulatory helix (Figure 50) (74). The 
phospho-sites, Ser12 and Thr19 are separated from the cis-regulatory helix by 
only 6-16 Å. The authors proposed that upon phosphorylation, the N-terminal tail 
can dissociate itself from its ordered position and can engage with the charged 
arginine residues. Based on these observations, we propose that the charged 
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arginine residues in the regulatory helices can act as finely tuned sensor that 
interacts directly with both G-6-P and the inhibitory phosphorylated residues 
thereby assisting the structural transition of the enzyme from one state to 
another. 
              
Figure 50. N-terminal phosphorylation. 
Ribbon representation of a dimer of CeGS. Each monomer of the dimer is 
colored separately and the black circle highlights the helix carrying the N-terminal 
phosphorylation sites.  
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4. Redox regulation of yeast Gsy2 
 Reversible redox regulation of enzyme activity via cysteine residues is a 
commonly occurring natural phenomenon. Upon oxidation, cysteines form 
disulfide bonds which can be restored to their initial state by reduction. Several 
studies have taken advantage of this chemistry and engineered di-sulfide bridges 
to activate/inhibit an enzyme and also to achieve stable structural conformations 
for the purpose of crystallization (97, 98). We took a similar approach to test the 
hypothesis that Gsy2 activity is dependent on the dynamics and distance 
between the regulatory helices of adjacent monomers. Arginines 581 and 592 
are positioned on either side of the regulatory helix facing each other across one 
of the molecular two-fold axes. Because of their proximity, formation of a di-
sulfide bond between directly opposed cysteine residues across the subunit 
interface should bring the regulatory helices an additional 2 Å closer. An inter-
subunit disulfide bond is consistent with the non-reducing SDS-PAGE as the 
non-reduced cysteine mutant migrated with a mass consistent with a tetramer. 
That the cysteines do not promote the formation of higher order aggregates is 
supported by gel-filtration analysis where only tetramers were observed. In 
addition, no other naturally positioned Cys residues in the GS subunits could 
form similarly inhibitory interactions with the newly introduced Cys residues at 
positions 581 and 592 (Figure 51). 
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Ribbon representation of a dimer of yGsy2 with the naturally occurring cysteine 
residues shown in magenta and the newly introduced cysteine mutants on the 
regulatory helix shown in yellow. The distance between the introduced cysteines 
and its closest naturally occurring cysteine residue is shown using dashed lines. 
The figure and the distance measurements were done using Pymol. 
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Figure 51.  Naturally occurring and rationally introduced cysteine residues 
in yGsy2. 
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The structural constraint on the conformational dynamics of the interface 
created by these disulfide bridges should not only inhibit the enzyme but will also 
render it unable to respond to G-6-P activation. The conformational tension can 
be released by reduction of the disulfide bonds. Consistent with our hypothesis, 
in the absence of reducing agents, Gsy2-R589C/592C possessed very low 
activity and the addition of up to 80 mM G-6-P could not activate the enzyme. 
This result demonstrated that G-6-P mediated activation of Gsy2 requires 
structural adaptations which are prevented by the engineered covalent restraint. 
However, addition of reducing agents like TCEP, DTT and BME restored the 
activity of Gsy2-R581C/R592C in a dose-dependent manner and also rendered 
the enzyme sensitive to G-6-P.  The resulting specific activity and activity ratio of 
the reduced enzyme is very similar to that of the control Gsy2-R581A/R592A 
mutant.  It should also be noted that both Gsy2-R581A/R592A and Gsy2-
R581C/R592C (in the presence of BME) had only ~ 50% of the wild type activity 
in the absence of G-6-P. This observation is consistent with the fact that both 
Arg589 and Arg592 are required to keep the enzyme in the basal state, so 
mutations of one to either alanine or cysteine leads to a partial reduction in basal 
activity level, by changing the energetics of the conformational set point. 
Our kinetic data also suggest that both Gsy2-R589A/R592A and Gsy2-
R581C/R592C (oxidized form) share similar kinetic properties with the 
phosphorylated Gsy2p. In all three cases, the largest changes were observed in 
the enzyme’s Vmax values with smaller changes to KM values, showing that UDP-
glucose binding is relatively unaffected either in the presence or absence of G-6-
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P. Similar observations were made earlier where both G-6-P binding and 
phosphorylation changed the KM values for glycogen without significantly 
changing the KM values for UDP-glucose. These results are consistent with the 
available structure evidence where access to the UDP-glucose binding site is 
much less affected by the conformational transitions, whereas the surface of the 
N-terminal domain where the acceptor arm of glycogen is thought to bind is 
impacted by these same structural transitions. 
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Figure 52. Structural model for the inhibited state and redox regulation of 
yeast GS. 
A. Flowchart showing the changes in the regulatory interface of yGsy2 upon 
multisite phosphorylation and G-6-P binding. B. Flowchart representation of the 
redox regulation of yGsy2 using the regulatory interface as the basis for 
comparison. Here the first and last arginine residues of the arginine cluster are 
mutated to cysteine residues. The basal activity of the enzyme and its ability to 
respond to G-6-P depends on the oxidation status of the cysteine residues. 
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In summary, we propose that redox regulation of Gsy2 serves as a 
functional model for GS phosphorylations. In our model, the inhibitory phospho-
serines/threonines on the C-terminal tail are expected to act as anchor points for 
a molecular strap by directly interacting with the arginine cluster across the 
subunit interface. This could promote regulatory helix closure similar to that 
observed in the Gsy2-R589A/R592A enzyme structure.   Multiple 
phosphorylation sites in the higher eukaryotes on both the C- and N-terminal 
extensions will provide additional anchoring points for the termini by increasing 
the effective concentration of these inhibiting interactions and further pushing the 
conformational equilibrium toward the inhibited state (Figure 51). Our Gsy2-
R581C/R592C mutant mimics this effect through disulfide bond formation (Figure 
51). G-6-P binding on the regulatory helix can disrupt the inhibitory interactions 
created by closure of the interface and push the regulatory helices apart, but only 
if there is an additional repulsive force available in the form of arginines 589 and 
592. In the absence of this opposing force or the presence of the disulfide bond 
in the oxidized form of the Gsy2-R581C/R592C enzyme, G-6-P cannot override 
the interactions that lock the tetrameric interface closed (Figure 51). These 
results suggest the key role played by Arg589 and Arg592 in establishing the 
reversibility of the inhibited state. 
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CONCLUSION 
The crystal structure of yGsy2 in the low activity state and the G-6-P 
bound activated state structures in complex with different UDP-sugars provide 
the structural and molecular basis for inhibition and substrate selection in 
eukaryotic GS and also extend our knowledge of the multiple conformational 
states of GS. Interestingly, the N-terminal domain motion of yGsy2 plays an 
important role in both productive catalysis and the activity state of the enzyme. 
For productive catalysis, the N-terminal domain of yGsy2 has to be able to close 
down on the substrates toward the C-terminal domain by ~13 degrees so that it 
can achieve the catalytically competent donor•acceptor complex. When bound to 
G-6-P, the tetrameric interface of the enzyme is “open” such that the N-terminal 
domain is free from interactions with the C-terminal domain. Under such 
circumstances, the subunits carrying the “productively bound” sugar donors in its 
active site can completely close the N-terminal domain toward the bound 
nucleotide sugar thereby bringing the acceptor chain in proximity to accept the 
sugar donor. However, when the enzyme is inhibited, the subunit contacts 
between the N-terminal domains and helices 15 and 16 in the opposing C-
terminal domain act as a wall that prevents domain closure by more than ~6 
degrees.  Thus, it is not possible for the inhibited state enzyme to fully capture a 
catalytically competent complex between an acceptor and donor substrate 
without reorganization of the tetrameric interface. The rate at which the 
reorganization of the tetrameric interface occurs in the inhibited state is likely to 
be much slower when compared to the activated state enzyme. To conclude, we 
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propose that binding of G6P pushes the conformational equilibrium toward a 
state that is more easily accessible for catalytic capture of the substrates, while 
phosphorylation or other actions that compact the tetrameric interface, push the 
conformational equilibrium toward states that cannot easily transition to 
productively capture the substrates for the transfer reaction. 
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